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Oxidized lipids are generated from (poly)unsaturated diacyl- and alk(en)ylacyl glycerophospholipids under conditions of oxidative stress. The
great variety of reaction products is defined by the degree of modification, hydrophobicity, chemical reactivity, physical properties and biological
activity. The biological activities of these compounds may depend on both, the recognition of the particular molecular structures by specific
receptors and on the unspecific physical and chemical effects on their target systems (membranes, proteins). In this review, we aim at highlighting
the molecular features that are essential for the understanding of the biological actions of pure oxidized phospholipids. Firstly, their chemical
structures are described as a basis for an understanding of their physical and (bio)chemical properties in membrane- and protein-bound form.
Secondly, the biological activities of oxidized phospholipids are discussed in terms of their unspecific effects on the membrane level as well as
their potential interactions with specific targets (receptors) affecting a large set of (signaling) molecules. Finally, the role of oxidized phospholipids
as important mediators in pathophysiology is discussed with emphasis on atherosclerosis.
© 2007 Elsevier B.V. All rights reserved.Keywords: Phospholipid oxidation; Membrane; Receptors; Inflammation; Apoptosis1. Structure and biological origin of oxidized
glycerophospholipids
Oxidation of fatty acids linked to the sn-1 and sn-2 positions of
glycerophospholipids leads to many different reaction products,
depending on chain length and degree of unsaturation. Enzyme-
catalyzed and non-enzymatic reactions may be involved in
(phospho)lipid oxidation in vivo. Lipid oxidizing enzymes include
lipoxygenase, myeloperoxidase, and NADPH oxidase, the latter
being a ROS generating enzyme that is involved in innate immune
defense and cell growth. A considerable amount of phospholipid
oxidation products detected in biological samples (tissues and
fluids) are likely to be formed by non-enzymatic reactions, since the
oxidized lipid isolates are mostly enantiomeric. PC is the main
phospholipid in all mammalian cells (40–50%) and lipoprotein
particles and thus, most oxidized phospholipids detected in
mammalian tissues contain the choline moiety. However, recently
oxidized PE has been found in the retina, which is a tissue that⁎ Corresponding author. Tel.: +43 316 873 6457; fax: +43 316 873 6952.
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doi:10.1016/j.bbadis.2007.04.009contains very high amounts of ethanolamine lipids [1]. In addition,
there are also reports providing evidence for the presence of
oxidized PS in the surface of apoptotic cells [2].
In eukaryotic phospholipids, the sn-1 position is either linked
to an acyl residue via an ester bond or an alkyl residue via an
ether bond, whereas the sn-2 position almost exclusively
contains acyl residues. The highly oxidizable polyunsaturated
fatty acids are preferably bound to the sn-2 position of
glycerophospholipids. Thus, most of the oxidized phospholipids
are modified at this position. At the sn-1 position of glycerol a
saturated fatty acid is usually bound. By contrast, plasmalogens
(alkenylacylglycerophospholipids) contain a vinyl ether bond in
position sn-1 and, as a consequence, they are also susceptible to
oxidative modifications at the sn-1 position.
1.1. Formation of oxidized diacyl glycerophospholipids
In mammalians, the sn-2 position of diacylglycerophospholi-
pids is frequently linked to polyunsaturated fatty acids (PUFAs)
that are prone to oxidative modification. The dissociation energy
of their bisallylic carbon–hydrogen bonds is low and thus, a
hydrogen atom can easily be removed followed eventually by
reaction with molecular oxygen [3]. The PUFAs found in
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fatty acids like AA and LA, but also all long-chain fatty acids
generated endogenously from AA or LA including docosahex-
aenoic acid or eicosapentaenoic acid. Oxidation of a single PUFA
in a glycerophospholipid like PA-PC results in a plethora of
different reaction products. The first steps in lipid peroxidation
consist of hydrogen abstraction, rearrangement of double bonds
and addition of triplet oxygen [4,5] leading to highly reactive
peroxyl radicals (Fig. 1). These radicals can undergo a large
variety of consecutive reactions including further hydrogen
abstraction, fragmentation generating truncated phospholipids
and different types of lowmolecular weight aldehydes (e.g. HNE,
MDA), or reactions via the isoprostane pathways (Fig. 1). Finally,
the oxidatively modified acyl chains of glycerophospholipids can
be released from the glycerol backbone by intracellular and
plasma phospholipases including PAF-acetyl hydrolases [6].
1.1.1. Formation of glycerophospholipids containing
peroxy fatty acids
Hydrogen abstraction of phospholipid-bound PUFAs, e.g. by
alkyl peroxyl radicals, leads to formation of hydroperoxide fattyFig. 1. Free radical-induced oxidation of 1-hexadecanoyl-2-eicosatetra-5′,8′,11′,14′-enoyl-
chain aldehydes, truncatedoxidized phospholipids, isoprostanes, isolevuglandins, and isothroacyl derivatives. These compounds subsequently decompose to
various products including 11-HETE or 15-HETE that are gen-
erated from AA. Different hydroperoxy fatty acids derive from
other PUFAs, e.g. oxidation of LA that leads to 9-HODE and 13-
HODE. Although fatty acid hydroperoxides are unstable and tend
to decompose by forming multiple reaction products (see below),
they can be found in human atherosclerotic plaques (Table 1). In
addition to free radical-mediated reactions, phospholipid hydro-
peroxides also can be generated through direct oxidation of
PUFA-PCs with singlet oxygen (Fig. 1).
1.1.2. Formation of truncated phospholipids and low
molecular weight aldehydes
Fatty acid hydroperoxides in PC are easily reduced. Frag-
mentation of the formed hydrodienes is a common reaction
leading to so-called γ-hydroxyalkenal PCs. γ-Hydroxyalkenal
PCs such as HOOA-PC, KOOA-PC, HOdiA-PC, and KOdiA-
PC [7,8] are not only characterized by truncated sn-2 acyl
chains, but also contain a terminal γ-oxygenated-α,β-unsatu-
rated aldehyde or carboxyl group function (Fig. 1). These
aldehydes share this structural motif with the well-known fattysn-glycero-3-phosphocholine (PA-PC) leads to many different products such as short-
mboxanes.RA, reaction involves rearrangement; Red, reaction involves reductive steps.
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mentation product of lipid peroxidation. Further fragmentation
of γ-hydroxyalkenal PCs leads to OV-PC and G-PC [8], which
have been found in atherosclerotic lesions at similar concentra-
tions compared with γ-hydroxyalkenal PCs (Table 1). In
addition to truncated phospholipids that are generated from
arachidonoyl PC, degradation products of linoleoyl PCs were
also found in biological material. The concentrations of these
PL-PC-derived γ-hydroxyalkenal analogs have also been found
to be higher in atherosclerotic tissue than in normal tissue.
However, the absolute amounts of these γ-hydroxyalkenal PCs
were lower as compared to their more highly oxidized relatives
ON-PC and ND-PC [8].Table 1
Content of different PA-PC oxidation products found in atherosclerotic lesions of h
HETEs Oxidized
phospholipid
Control/healthy
[ng/μg arachido
11-HETE –
15-HETE –
Truncated oxidized phospholipids Chow diet a
[ng/mg wet tissu
POV-PC 41.6±7.0
23.1±3.4
PG-PC 35.3±5.5
18.6±2.0
WHHL b3 mon
[ng/mg PAPC]
POV-PC 0.92±0.18
PG-PC 0.82±0.48
HOOA-PC 0.62±0.21
KOOA-PC 0.59±0.21
HOdiA-PC 0.26±0.18
KOdiA-PC 0.05±0.05
Isoprostanes [pmol/μmol pho
15-iso-PGF2 0.045–0.115
F2α isoprostane
b 0.16–0.44
[pg/mg dry tissu
F2-isoprostanes 11.4±6.2
Chow dieta
[ng/mg wet tissu
PEI-PC 29.2±3.1
18.9±1.4
Isolevulglandins Healthy subject
Plasma protein
iso[7]LGD2 3500±100
isoLGE2 121
iso[4]LGE2 1691±252
WHHL is Watanabe hereditable hyperlipidaemic rabbit; NZW is New Zealand Whi
a All values recalculated to 1-palmitoyl-sn-phospholipids and summed up. For va
acid-derived hydroperoxide containing fatty acids see ref. [144].
b Derived from eicosapentaenoic acid.
c Compound detected in [145], but structure was determined doubtlessly later byVery recently, it was reported that a subset of γ-hydroxyalk-
enal PCs can react intramolecularly via a hemiacetal interme-
diate to form a new class of oxidized phospholipids containing a
terminal furyl moiety at their sn-2 position [10]. This type of
oxidized phospholipids was not only generated in vitro but,
more importantly, also found ex vivo in brain tissues following
cerebral ischemia.
1.1.3. Non-enzymatic isoprostane formation
Enzymatic formation of prostaglandins by cyclooxygenases
exclusively leads to compounds with trans stereochemistry of the
long-chain substituents in the prostane ring and no region- orumans and other mammalian atherosclerosis models
Atherosclerosis Tissue type Reference
nic acid]
0.84±0.24 Human lesions [144]
0.66±0.24 Human lesions [144]
Atherogenic dieta
e weight]
183.1±54.5 NZW rabbit aortas [48]
63.7±11.9 rabbit aortas [145]
104.2±26.3 NZW rabbit aortas [48]
45.4±11.3 rabbit aortas [145]
ths WHHL N6 months
3.5±0.39 WHHL rabbit aortas [83]
2.3±0.05 WHHL rabbit aortas [83]
3.2±0.72 WHHL rabbit aortas [83]
3.1±0.89 WHHL rabbit aortas [83]
1.4±0.10 WHHL rabbit aortas [83]
0.62±0.07 WHHL rabbit aortas [83]
spholipids]
1.31–3.45 Human lesions [146]
5.6–13.8 Human lesions [146]
e weight]
75.9±29.3 Human lesions [147]
Atherogenic dieta
e weight]
141.5±45.2 NZW rabbit aortas [48]
58.6±12.9 rabbit aortas [19,145] c
s Subjects with CHD
adduct level [pmol/mL]
8500±3100 Human [26]
306 Human [148]
2224±439 Human [26]
te rabbit.
lues of the PLPC-derived truncated phospholipids see ref. [83] and for linoleic
[19].
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tanes always yields derivatives that contain the thermodynami-
cally more stable cis stereochemistry and racemic mixtures of
various isomers. Free PUFAs as well as PUFAs esterified to
phospholipids appear to serve as substrates for non-enzymatic
formation of isoprostanes in vivo [11]. In contrast, phospholipid-
bound PUFAs are not modified by cyclooxygenases since these
enzymes only accept free fatty acids as substrates [12]. Addition
of two molecules of oxygen to one molecule of arachidonoyl
phospholipid generates four isomers of bicyclic endoperoxide
intermediates. This is due to nonregioselective abstraction of
hydrogen atoms from arachidonoyl PC forming three regioiso-
meric pentadienyl radicals from which four regioisomeric
peroxyeicosatetraenoyl radicals are generated by reaction with
oxygen. Subsequently four structurally isomeric endoperoxide
intermediates are formed (Fig. 1), namely 5-isoPGG2-PC, 8-
isoPGG2-PC, 12-isoPGG2-PC, and 15-isoPGG2-PC. Although
the probability of abstraction is the same for the three bisallylic
hydrogen atoms in AA, very different amounts of the four
isoPGG2-PC regioisomers were found in rat liver [13]. The 5- and
15-isoPGG2-isomers, which are more abundant, are generated
from endoperoxides that cannot undergo further oxidation or
cyclization and thus, accumulate in biological fluids and tissues
[14]. Reduction of the isoPGG2-PCs yield four regioisomeric
endoperoxide isoPGH2-PCs that can be further reduced to form
isoPGF2-PCs, each consisting of eight racemic diastereomers.
Alternatively, the four isoPGH2-PCs can undergo various
rearrangements, leading to isothromboxanes or E2/D2-isopros-
tanes (Fig. 1). F2-isoprostanes are formed together with E2/D2-
isoprostanes in a competitivemanner. Recently, it has been shown
that this process depends on the redox status of the cell. Under
conditions of oxidative stress, the formation of both types of
isoprostanes is more pronounced than under normal conditions,
but depletion of cellular antioxidants favors the formation of E2/
D2-isoprostanes as compared to F2-isoprostanes [15]. Conse-
quently, the ratio of E2/D2-isoprostanes to F2-isoprostanes is a
good measure for the reducing capacity in that tissue. F2-
isoprostanes are stable compounds and thus, represent in vivo
markers of lipid peroxidation in biological fluids and tissues.
Except for conditions of severe oxidant injury, free E2/D2-
isoprostanes are undetectable in normal plasma, but can easily be
measured in tissues. E2/D2-isoprostanes are not the final products
of the isoprostane pathway. They can be dehydrated to give
reactive cyclopentenone A2/J2-isoprostanes [16] (Fig. 1). These
highly reactive electrophiles form Michael adducts with cellular
thiols that become rapidly metabolized by glutathione trans-
ferases. Water-soluble glutathione conjugates are generated that
can be quantified in human urine [17].
In addition to the endoperoxide core, the allylic hydroperox-
ide group of isoPGG2-PC can also undergo dehydration thus
generating allylic epoxides [18] from which the 5,6-epoxyiso-
prostane E2 derivatives are obtained. These reaction products are
commonly known as PEI-PC [19]. They also can be dehydrated
to the corresponding A2-isoprostane (PEC-PC). High amounts
of PEI-PC have been found in atherosclerotic lesions that are
comparable to the concentrations of the truncated phospholipids
OV-PC and G-PC in the diseased vascular tissue (Table 1).Recently, it has been shown that 15-isoPGE2 undergoes
keto-enol tautomerization in aqueous buffer leading to
the formation of the prostaglandin PGE2 [20]. From this
observation it was concluded that prostaglandins also can
be generated via the non-enzymatic isoprostane pathway in
vivo.
1.1.4. Formation of isolevuglandins
A completely different rearrangement of isoPGH2-PC,
involving migration of one of the bridgehead hydrides in
combination with cleavage of the endoperoxide O\O and a
C\C bond (bridge carbon), yields one of two isomeric, acyclic,
keto-aldehyde-PCs (isolevuglandin-PCs, Fig. 1) [21]. These
phospholipids can be generated from all four isomeric isoPGH2-
PCs, thus giving rise to the formation of eight highly reactive
diastereomeric oxidation products [22]. This type of rearrange-
ment reaction may also occur in vivo at rates comparable to
endoperoxide decomposition leading to isoprostanes. While
many free isoprostanes can easily be isolated from biological
fluids and tissues, the highly reactive isolevuglandins have been
overseen in biological samples for a long time and were only
discovered as protein-adducts using an immunological approach
[22]. Isolevuglandins rapidly form Schiff bases [23] and pyrroles
[24] with the ε-amino groups of protein lysyl residues, that are
eventually oxidized, generating lactam and hydroxylactam end
products [25]. The mean levels of all protein-adducts of isole-
vuglandins appear to be highly increased in plasma from in-
dividuals with advanced atherosclerosis as compared to controls
[26]. Isoprostanes, which are rapidly cleared from the blood
stream, may be considered reliable “snapshots” of oxidative
stress. In contrast, isolevuglandins rapidly bind to proteins in a
covalent manner. Since many plasma proteins have half-lives of
several weeks [27], isolevuglandins accumulate over days or
weeks and therefore, have been suggested as a cumulative index
for oxidative injury [26].
1.2. Oxidized alkyl glycerophospholipids
Free radical-induced oxidation of 1-O-hexadecyl-2-arachi-
donoyl-PC results in generation of the so-called C4-PAF
analogs Butanoyl-PAF and Butenoyl-PAF (Fig. 2), which was
first shown by Marathe and colleagues [28]. HAz-PC is another
oxidized alkyl phospholipid that was detected in oxLDL after
removal of the large excess (99.5%) of diacyl phospholipids by
phospholipase A1-catalyzed hydrolysis [29]. Analysis of the
remaining phospholipids revealed that besides the C4-PAF
analogs, HAz-PC (Fig. 2) was the main oxidation product of
alkyl glycerophospholipids in oxLDL.
From plasmalogens (alkenylacylglycerophospholipids),
which contain a vinyl ether bond in position sn-1 of glycerol,
oxidation products were found that are modified in the sn-1
and/or sn-2 positions. 1-Lyso-2-acylglycero-3-phosphocholine
and 1-formyl-2-acylglycero-3-phosphocholine [30] are pro-
ducts of oxidative and hydrolytic degradation at the sn-1
position. Oxidative modifications of the sn-2 acyl position of
plasmalogens can be the same as described for diacyl
phospholipids (see Section 1.1). The amounts of oxidized
Fig. 2. Chemical structures of platelet-activating factor (PAF) and PAF-like
lipids that can be formed during oxidation of alkylacylphospholipids.
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been determined yet.
2. Biophysical properties of phospholipid oxidation products
Biomembranes contain different phospholipid classes (head-
group heterogeneity), subclasses (acyl, alkyl chains) and species
(chain length and unsaturation). The differences in chemical
structure determine the physical properties of these important
membrane and lipoprotein components. PC tends to form
bilayers with little curvature, while PE imposes a negative
curvature on these lipid bilayers [31]. Conversely, introduction
of the micelle-forming LPC into a PC membrane results in a
positive curvature. In addition to the polar headgroups the
polarity, length and unsaturation of the phospholipid acyl chains
have also an impact on physical membrane properties. Thus,
phospholipid oxidation products (Fig. 1) are very likely to
change the properties of biological membranes, because their
polarity and shape may differ significantly from the structures
of their parent molecules. Thus, they may unspecifically alter
lipid–lipid and lipid–protein interactions and, as a consequence,
also membrane protein functions.
Since natural biomembranes are very complex structures,
defined biophysical studies on the impact of phospholipid
oxidation on membrane properties have been performed using
artificial membrane systems including small unilamellar
vesicles (SUV), multilamellar vesicles (MLV) or phospholipid
monolayers.Upon oxidation of PC-SUVs in an air atmosphere, the
transbilayer movement of PC increases. Information about
effects of lipid oxidation on phospholipids mobility in SUVs
has been obtained from time-resolved fluorescence anisotropy
and excimer/monomer ratios of pyrene labeled phospholipids
[32,33]. It was inferred from fluorescence correlation spectros-
copy studies that the SUVs containing higher amounts of
unsaturated phospholipids had a higher negative curvature thus
facilitating the partition of the oxidant into the hydrophobic
membrane region. Once the unsaturated phospholipids are
oxidized (loss of double bonds), the membrane lipids are more
rigid, showing lower lateral diffusion and decreased local lipid
mobility.
A recent EPR spectroscopy study used β-n-doxylstearoyl-PC
as a spin label reports on the detection of phase separations in
MLV containing different mixtures of DP-PC, LP-PC and
oxidized LP-PC. Oxidized LP-PC induced phase separation in
the densely packed DP-PC-rich membranes, whereas lipid
mobility is almost unaffected by the oxidized lipids in more
fluid LP-PC-rich membranes [34]. Very recently, two oxidatively
modified diacyl PCs, namely PAz-PC and PON-PC, have been
investigated in DP-PC monolayers. The authors observed phase
separation, upfolding of the truncated polar fatty acid chain
towards the lipid–water interface and, as a result, monolayer
expansion. Most of the oxidized phospholipids partitioned finally
into the aqueous subphase [35].
Studies on isolated mitochondria showed that oxidation of
membrane lipids destroyed lipid bilayer packing in vitro [36]
and in vivo [37]. Oxidized phospholipids also influence the
functions of membrane proteins. In this context, impairment of
ion transport and negative effects on membrane proteins have
been observed [38,39].
3. Biochemical reactivity of phospholipid oxidation products
Depending on their chemical structure, oxidized phospholi-
pids can interact with other biomolecules in a purely physical
manner or by chemical reaction. The spectrum of chemical
reactivity of phospholipid oxidation products is very broad.
Modification reactions may lead to stable (e.g. F2-isoprostanes)
or reactive compounds (e.g. isolevuglandins or γ-hydroxyalk-
enals). Some of these reactions can be considered relevant for
detoxification, but most are leading to modification of important
functional molecules and thus, negatively influence their
activity within a cell. Incorporation of oxidized phospholipids
into cells can be mediated by direct uptake and integration into
membranes or via receptor-mediated pathways. In the following
sections we separately discuss these basic mechanisms
underlying the action of oxidized phospholipids.
3.1. Detoxification of oxidized phospholipids
Most truncated phospholipids and the oxidation products that
are formed via the isoprostane pathway contain an oxidatively
modified acyl chain at their sn-2 position which is more polar
than the original PUFA. Phospholipases play an important role
in the metabolism of these compounds. Calcium-independent
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and calcium-dependent secretory (sPLA2) phospholipases were
shown to release the modified sn-2 carboxylic acids from
oxidized phospholipids [40] thus generating 2-lyso-phospholi-
pids and free oxidized fatty acid derivatives. Platelet activating
factor acetylhydrolase (PAF-AH, Lp-PLA2) hydrolyzes glycer-
ophospholipids with short acyl chains, including PAF and
truncated oxidized phospholipids (e.g. OV-PC, G-PC). PAF-AH
might play an anti-inflammatory role in human diseases by
preventing the accumulation of oxidized phospholipids [41].
However, the role of PAF-AH in atherosclerosis is controversial
because the production of LPC and oxidatively modified free
fatty acids can also promote the pathogenesis of atherosclerosis.
For instance, Carpenter et al. showed that LPCwas more toxic to
macrophages than oxidized LDL containing oxPA-PCs and that
toxicity and induction of apoptosis was decreased in the
presence of a PAF-AH inhibitor [42,43]. Inhibition of LDL-
associated PAF-AH in hypercholesterolemic rabbits also
suggests that this enzyme might have pro-atherogenic effects
[44]. Furthermore, elevated plasma levels of PAF-AH were
recently shown to be a novel cardiovascular risk marker and an
independent predictor of coronary artery disease in men [45]. On
the contrary, overexpression of PAF-AH in Chinese hamster
ovary-K1 cells suppressed oxidative stress-induced apoptosis
[46]. In addition, data from our laboratory suggest that serum
phospholipases, which hydrolyze oxidized phospholipids,
protect vascular smooth muscle cells from apoptotic cell death
[47]. Furthermore, other studies show that LPC, unlike oxidized
phospholipids, is not able to trigger inflammatory transcription
events like IL-8 expression [48]. Tselepsis et al. concluded that
PAF-AH or PAF-AH-like activity associated with HDL particles
plays a predominantly anti-atherogenic and anti-inflammatory
role through its reduction of monocyte adhesion to the
endothelium, its ability to abrogate the biological activity of
minimally modified LDL, and finally its capacity to attenuate
phospholipid oxidation and induce reduction in lesion volume
via a decrease in macrophage homing in animal models [49].
Thus, depending on its location (LDL-associated vs. HDL-
associated), PAF-AH plays a dual role in the pathogenesis of
atherosclerosis, serving a protective function against mild
inflammatory and oxidative stress but promoting the develop-
ment of pro-atherogenic states under more severe states in which
excess amounts of oxidized phospholipids are produced [41].
Furthermore, it is also dependent on the cell type and the
progression of the disease, whether inhibition of PAF-AH exerts
anti- or pro-atherogenic effects.
F2-isoprostanes, which are considered markers for oxidative
stress in human body fluids (e.g. urine) are also released from
their oxidized glycerophospholipids by the action of PLA2s [6].
Fatty acid hydroperoxides which are released by the action of
the same enzymes are eventually reduced and thus detoxified by
cytosolic glutathione peroxidase (GPx) [40,50]. In this context,
it is noteworthy that oxidized phospholipids and oxLDL
enhance the expression of glutamate-cysteine ligase, the key
enzyme of glutathione formation [51]. In addition, GPxs which
directly reduce phospholipid hydroperoxides were recently
detected in mammalian cells [52–54].3.2. Chemical reactions of phospholipid oxidation products
Many phospholipid oxidation products contain chemically
reactive groups including aldehydo ore keto carbonyls, epoxides
or double bonds in conjugation to carbonyl groups (Figs. 1 and 2).
As a consequence, oxidized phospholipids can undergo chemical
reactions with a large variety of biological molecules containing
nucleophilic functional groups. Representative examples are
described in the following chapters. In addition, it should again be
emphasized here that the reactive carboxylic acids can be released
from the parent phospholipid by PLA2s (see Section 3.1). In free
form, they will undergo qualitatively the same reactions they
would perform in the phospholipid-bound state. However, the
target molecules might be different, since the polarities and thus,
the preferred cellular compartments are different, too.
3.2.1. Reactions of aldehydes
Aldehydes can form Schiff bases with primary amino groups
of e.g. proteins and amino phospholipids (Fig. 3A), thus affecting
structure and function of these biomolecules. In addition,
aldehydes can be modified by oxidation or reduction leading to
formation of carboxylic acids and alcohols, respectively. Studies
with specific enzyme inhibitors and cells overexpressing aldose
reductase provided evidence that human aldose reductase is
responsible for the reduction of free aldehydes such as HNE and
the aldehydo phospholipid POV-PC [55,56].
3.2.2. The γ-hydroxyalkenals—much more reactivity!
Members of this group of oxidized phospholipids are either
truncated phospholipids or free γ-hydroxyaldehydes. The latter
are released from their glycerophospholipid backbone by the
action of phospholipases or directly generated by free radical-
induced peroxidation of linoleates or arachidonates. HNE is the
most extensively studied derivative. It is an aldehyde possessing
three reactive groups and undergoes multiple chemical re-
actions. Since it is a vinyl aldehyde, the carbon atom in β-
position relative to the carbonyl group has a partial positive
charge which is further enhanced by the inductive effect of a
hydroxyl group at the γ-carbon. In addition, all three functional
groups may act in concert contributing to its high reactivity. One
of the biologically most important reactions of γ-hydroxyalk-
enals is the addition of thiol or amine nucleophiles to its
electrophilic β-carbon atom (Michael addition, Fig. 3B). The
resulting Michael adduct as well as the γ-hydroxyalkenal itself
contains a γ-hydroxyaldehyde moiety that can further react
either with alcohols, thus forming hemiacetals and acetals, or
intramolecularly forming cyclic hemiacetals (Fig. 3B). The
Michael addition of GSH to HNE is catalyzed by glutathione-S-
transferases. In vivo, HNE forms the conjugate mercapturic acid
with glutathione leading to detoxification and urinary excretion
of HNE [57].
The second major reaction of γ-hydroxyalkenals is the
formation of Schiff bases with primary amines (Fig. 3B). In a
consecutive reaction pyrroles are formed by dehydration and
cyclization of the adducts. 2-Pentylpyrroles that are reaction
products of HNE with the ε-amino group of protein lysines were
found in vivo. The levels of these protein adducts with HNE and
Fig. 3. Reactions of aldehydes formed by phospholipid oxidation. (A) Aldehydes can form Schiff bases with primary amines and bifunctional aldehydes can lead to
crosslinking of two primary amines. (B) γ-hydroxyalkenals are much more reactive and can react via various pathways, either with nucleophiles to form hemiacetals
(Michael addition), or with primary amines via Schiff bases to form pyrroles.
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in patientswith atherosclerosis as compared to healthy individuals
[58,59]. Schiff bases of γ-hydroxyalkenals with proteins can
subsequently undergo Michael additions to other molecules thus
forming protein–protein cross-links. In addition to proteins,
amino lipids such as PE can also form Schiff bases with γ-
hydroxyalkenals and their corresponding pyrrol end products
[60]. Michael addition of the DNA base guanosine gives a
tricyclic adduct in vivo that is considered to be at least in part
responsible for the gentoxic effect of HNE [61]. Another reactive
aldehyde, 2,3-epoxy-4-hydroxynonenal has also been proposed
to modify DNA bases, but the mechanism of this reaction is still
not fully understood. An etheno guanosine adduct of this
aldehyde was found in human lung tissue [62]. From systematic
studies in vitro, evidence is available that aldehyde phospholipids
such as POV-PC also form addition products with proteins [44].
Lipid–protein adducts have also been found in tissue using
antibodies specific for the choline headgroup of the protein
associated oxidized phospholipids (see Section 3.3.5).
3.2.3. Reactivity of isolevuglandins and levuglandins
Levuglandins, that are formed enzymatically or none-
nzymatically as well as free radical-generated isolevuglandins
are γ-dicarbonyl compounds which undergo Paal–Knorr con-
densation with primary amines leading to the formation of
pyrroles [24]. This reaction occurs via Schiff base formation and
tautomerization to the corresponding enamine (Fig. 4A). These
very efficient reactions are responsible for the formation of
LGE2-protein adducts. The reaction of LGE2 with albumin is
two orders of magnitude faster than the condensation of HNE
with the same protein [25]. The condensation products
dehydrate to form pyrroles that are slowly oxidized in the
presence of oxygen or peroxyl radicals. Lactams and hydro-
xylactams are generated which are stable end products [22,25].Alternatively, the Schiff bases that can be stable for minutes
may react with a second primary amine leading to aminal
formation. The primary amine can either be a low molecular
compound or another free lysyl group of a protein (Fig. 4B).
The latter reaction of levuglandins and isolevuglandins leads to
cross-linking of proteins and formation of high molecular
weight protein–protein adducts in vitro [63]. Free radical-
induced isoprostane formation and overproduction of prosta-
noids through the cyclooxygenase pathway have been reported
to contribute to pathophysiologic courses by protein cross-
linking in vivo [64,65].
3.3. Receptors for oxidized phospholipids
Oxidized phospholipids are largely recognized by a molec-
ular machinery that was evolved to protect an organism from
invading microorganisms or transformed and damaged cells.
Cell surfaces display germline-encoded receptors for conserved
pathogen-associated molecular patterns (PAMP), such as
lipopolysaccharide (LPS), peptidoglycans, lipoteichoic acid,
or dsRNA [66]. These pattern-recognition receptors (PRR) can
reside on the cell surface, like the scavenger receptors [8,67] or
Toll-like receptors (TLR), or they circulate in the blood stream
like C-reactive protein (CRP) [68], LPS binding protein (LPB)
and plasma CD14 [69] (Fig. 5).
3.3.1. Scavenger receptors
The oxidized lipids of oxLDL were supposed to be solely
responsible for the cellular uptake and recognition of the particle
via CD36, a member of the scavenger receptor class B family
[70]. This assumption is supported by the observation that
macrophages from CD36 knockout mice were resistant to foam
cell formation in vitro and that CD36-dependent signaling
cascades were necessary for murine macrophage foam cell
Fig. 4. Formation and reactions of isolevuglandins. (A) Isolevuglandins are formed by decomposition of tricyclic H2 (iso)prostanes and subsequently can react with
proteins to form protein adducts. (B) Isolevuglandins can crosslink proteins.
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lesions than wild-type mice [72]. CD36 is a multi-ligand recep-
tor, that recognizes amongst others oxLDL [73,74], thrombo-
spondin [75,76], PS [70,77], and long-chain fatty acids [78]. The
binding sites for oxLDL, thrombospondin [79,80] and PS [81]
are different. Several studies have identified oxidized phospho-
lipids derived from PL-PC and PA-PC as ligands of CD36. The
structural requirement for high affinity binding to CD36 is a γ-
oxygenated-α,β-unsaturated aldehyde or carboxyl group at the
sn-2 position of truncated phospholipids [8]. Keto dicarboxylic
monoesters KOdiA-PC and KDdiA-PC (Fig. 1) derived from
PA-PC and PL-PC, respectively, are the oxidized phospholipids
with the strongest CD36 binding properties. However, the same
lipids are not recognized by scavenger receptor A1, except they
are bound to apoB [82]. The fatty acid chains (e.g. oleate versus
palmitate) at the sn-1 position did not influence CD36 binding
[8]. Addition of just a few molecules of these keto dicarboxylic
monoesters to liposomes prepared from unoxidized LDL lipids
already led to macrophage binding, uptake of the entire particle,
cholesterol loading and foam cell formation [83].3.3.2. Toll-like receptors
TLRs are type 1 transmembrane receptors that are highly
conserved throughout evolution containing an intracellular Toll/
IL-1 (TIR) domain and an extracellular leucine-rich domain. In
mammalians, 12 different TLRs have been identified to date.
They are critical to the function of both innate and adaptive
immunity and are expressed in cells regulating inflammation and
immunity such as macrophages, endothelial cells or dendritic
cells. TLRs detect and bind PAMPs and their ligands include LPS
(recognized by TLR4) and various bacterial lipids, such as
lipoteichoic acid, peptidoglycan and lipopeptides that are
recognized by TLR2 heterodimers with TLR1 or TLR6. In
contrast to these cell surface-expressed TLRs, there are also
intracellular TLRs that bind to both viral double stranded RNA
and DNA. But, in addition to recognition of bacterial- and viral-
derived molecules, various endogenous ligands that are produced
in response to stress or tissue injury have recently been suggested
[84]. Interestingly, TLR1, TLR2 and TLR4 are expressed in both
mouse and human atherosclerotic lesions and are upregulated by
oxidized LDL. [85]. Furthermore, phospholipid oxidation
Fig. 5. Different pure oxidized phospholipids activate distinct signaling pathways leading to various inflammatory responses or apoptosis. For simplification, the most
relevant pathway components are shown. aSMase, acid sphingomyelinase; COX-2, cyclooxygenase 2; CREB, response element-binding protein; CS-1, connecting
segment 1; EGR-1, early growth response protein 1; ERK1/2, extracellular signal-related kinases 1/2; E-Sel, E-selectin; G-PC, glutaric acid ester of LPC; HODE,
hydroxyoctadecanoic acid (position of hydroxyl group not specified); HO-1, heme oxygenase 1; ICAM, intercellular adhesion molecule; IL-8, interleukin 8; JNK,
c-Jun N-terminal kinase; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein 1; NFAT nuclear factor of activated T-cells; NF-κB, nuclear factor kappa
B; OV-PC, 5-oxovaleric acid ester of LPC; p38, p38 mitogen-activated protein kinase; PAF platelet-activating factor; PAF-R, PAF receptor; PEI-PC, 1-hexadecanoyl-
2-(5,6-epoxyisoprostane-E2-oyl)-sn-glycero-3-phosphocholine; PI3K, phosphatidylinositol-3-kinase; PKA, protein kinase A; PKC, protein kinase C; PM, plasma
membrane; PPAR, peroxisome proliferator-activated receptor; SR-A1, scavenger receptor A1; SREBP, sterol regulatory element-binding protein 1; STAT3, signal
transducer and activator of transcription 3; TLR-4, Toll-like receptor 4; VCAM, vascular cell adhesion molecule; VEGFR2, vascular endothelial growth factor receptor
2.
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inhibits LPS-induced inflammation by interaction with plasma
LPB and CD14 in endothelial cells and macrophages. POV-PC
and KOdiA-PCwere identified as the main components of oxPA-
PC that inhibit ligand binding to TLR4 and TLR2 [69]. In-
terestingly, oxPA-PC itself also shows pro-inflammatory effects
by inducing interleukin-8 (IL-8) synthesis via TLR4, but not
CD14 [67].
3.3.3. PAF-receptor
A variety of mammalian cells synthesize the lipid mediator
PAF under inflammatory conditions. PAF receptor (PAF-R)
signaling is linked to various second messenger networks
through phospholipases leading to calcium fluxes, PI cycling,
and activation of phosphorylation. It shows several hundred-fold
specificity for the sn-1 ether bond of PAF compared with the 1-
acyl analog and a pronounced although lower specificity for ashort sn-2 acyl chain and the PC headgroup [3]. Oxidation of AA
in alkylacyl PCs of LDL leads to formation of short chain PAF-
analogs (Fig. 2) which are ten-fold less efficient receptor ligands
than PAF, but still potent PAF mimetics [28]. In contrast, diacyl
phospholipids with short sn-2 acyl chains several hundred-folds
less efficiently bind to the PAF receptor. All the studies indicated
above compared the receptor binding capacities of PAF and
oxidized phospholipids indirectly by measuring the induction of
intracellular calcium fluxes. Recent binding/displacement
experiments in cultured human macrophages were performed
using [3H]PAF and POV-PC as competitors. The binding affinity
of POV-PC was only 3.4 times lower as compared to PAF [87],
although much larger differences in calcium flux were found
between PAF and POV-PC as compared to earlier studies [28].
Obviously, the conformational changes induced by POV-PC are
not sufficient to activate the receptor in a manner comparable to
PAF.
727G.O. Fruhwirth et al. / Biochimica et Biophysica Acta 1772 (2007) 718–7363.3.4. G Protein-coupled receptors
Parhami et al. provided evidence that G protein-coupled
receptors (GPCR) may become activated by oxidized phospho-
lipids [88]. They found that mmLDL in which mainly the lipids
are oxidized increased cyclic AMP levels in endothelial cells via
a putative Gαs-coupled receptor. According to a recent report
[89], the mammalian GPCR G2A, which was originally iden-
tified as a stress inducible GPCR [90], responds to oxidized free
fatty acids. 9-HODE and 11-HETE were the most potent
derivatives in mediating intracellular calcium mobilization. 9-
HPODE was also a potent ligand, whereas 13-HODE and 13-
HPODE showed weaker affinities. In general, only free
oxidized fatty acids were potent ligands and therefore it was
concluded that hydrolytic release of the oxidized fatty acids
from oxidized PC was required for the observed intracellular
calcium mobilization via G2A [89]. Very recently, it was shown
that the GPCRs prostaglandin E2 receptor (EP2) and prosta-
glandin D2 receptor (DP) are activated by PEI-PC. EP2 is
expressed in endothelial cells, smooth muscle cells, and mac-
rophages, while DP is not expressed in endothelial cells [91].
The epoxyisoprostane structure is required for receptor ac-
tivation and the most potent activator of EP2 contained such an
element.
3.3.5. Recognition by antibodies
The development of atherosclerosis is intimately associated
with the immune response [92–94]. A number of potential
antigens is present in lesions that could be responsible for the
activation or a response of the immune system including
bacteria and viruses, heat shock proteins, modifications of
arterial wall components and lipoproteins and importantly,
oxidatively modified lipoproteins and their products [95–97].
There is now considerable evidence that neo-epitopes generated
on oxidized LDL are important and even dominant antigens that
drive this immune response. The dominant epitopes in oxLDL
are oxidized phospholipids either present in free form or as
lipid–protein adducts [98]. Any phospholipid containing a
polyunsaturated fatty acid is susceptible to oxidation and can
generate an antigenic neo-epitope. Many of the so-called anti-
phospholipid antibodies that are associated with rheumatologic
diseases or with the primary Antiphospholipid Antibody
Syndrome (APS) are antibodies directed against oxidized
phospholipids [99]. Cardiolipin is still the standard phospho-
lipid which is usually used for anti-phospholipid antibody
screening. Antibodies purified from APS patients bound only to
oxidized cardiolipin but not to an unmodified cardiolipin analog
that is stable against oxidation. Furthermore, β2GP1 which is a
cofactor required for binding of anti-cardiolipin antibodies is
recognized by APS sera only when bound to oxidized
cardiolipin [100].
OxLDL-specific E0 antibodies, which were generated from
apoE-deficient mice also recognize oxidized phospholipid
epitopes [98]. The antibody EO6 recognizes the oxidized
phospholipid POV-PC but not unoxidized PA-PC. EO6 spe-
cifically is able to bind to an adduct of POV-PC with BSA.
Furthermore, EO6 specifically binds to apoptotic but not to
viable cells and was able to blocks macrophage phagocytosis ofapoptotic cells [101]. Apoptotic cells are rich in oxidized
phospholipids and, as a consequence, in protein bound lipid
epitopes that are recognized by E06 on the cell surface.
4. Biological effects and disease
Evidence is growing that oxidized phospholipids play a key
role in the development of several chronic diseases including
atherosclerosis. Oxidized phospholipids have been shown to
accumulate in atherosclerotic lesions [102] and show a great
variety of biological effects in vivo and in vitro. They are being
identified as essential molecular components that are respon-
sible for the pathophysiologic actions of oxidized LDL. This is
just one more example showing that the use of chemically
defined compounds rather than complex lipoprotein mixtures
helps very much to gain a better understanding of the biological
functions of complex lipid systems such as lipoproteins and
membranes. In this chapter we will focus on how defined
oxidized phospholipids can trigger immune response, inflam-
mation, apoptosis and the underlying signaling pathways.
4.1. Oxidized phospholipids, inflammation and inflammatory
signaling
Atherosclerosis is a chronic inflammatory disease which is
characterized by specific invasion of monocytes and T-cells into
the vascular wall, while neutrophils are essentially not present in
atherosclerotic lesions. In acute inflammation, cytokines and
bacterial products like interleukin-1 (IL-1), tumor necrosis factor α
(TNFα) or LPS activate the classical NF-κB pathway. The latter in
turn triggers expression of adhesion molecules like vascular cell
adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-
1 (ICAM-1), or the neutrophil-binding molecule E-selectin, which
results in adhesion of both monocytes and neutrophils. In contrast,
mmLDL, oxPA-PC and one of its active compounds, pure POV-
PC, activate endothelial cells to specifically bind monocytes but
not neutrophils, which is a hallmark of chronic inflammation
[103]. Furthermore, oxPA-PE and oxPA-PS also were found to
induce monocyte adhesion to endothelial cells [48]. Monocyte
adhesion to endothelial cells after stimulation with these oxidized
lipids involves the activation of an α5β1 integrin and increased
deposition of connecting segment-1 (CS-1)-containing fibronectin
on the cell surface [104]. It is not mediated by surface expression
of the adhesion molecules VCAM-1, ICAM-1 or E-Selectin, or
activation of the classical NF-κB pathway. POV-PC and oxPA-PC
induce monocyte binding to endothelial cells by a cAMP-coupled
pathway involving protein kinase A (PKA), R-Ras and PI3K
[105].
In contrast to POV-PC, the more highly oxidized phospho-
lipid PG-PC induces both monocyte and neutrophil binding to
the endothelium. PG-PC leads to the expression of VCAM-1
and E-selectin on the endothelial surface, but does not affect
CS-1 expression [48]. These data provide evidence that POV-
PC, PG-PC and probably also other pure oxidized phospholi-
pids are important regulators of leukocyte–endothelial cell
interactions. POV-PC may play a dominant role in chronic
inflammation under circumstances where monocyte adhesion
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POV-PC and PG-PC in the cells whether a chronic (monocytic)
or an acute (monocytic and neutrophil) inflammation prevails
[106].
In the past decade most of the studies dealing with signaling
effects of oxidized phospholipids used oxPA-PC, a mixture of
oxidized phospholipids that induces a plethora of biological
effects. These include stimulation of tissue factor (TF) expression
in human umbilical vein endothelial cells (HUVEC) involving
protein kinase C (PKC), extracellular signal-related kinases 1 and
2 (ERK1/2), p38 mitogen-activated protein kinase (p38-MAPK)
and increased intracellular calcium, ultimately leading to ac-
tivation of the transcription factors endothelial growth related-1
(EGR-1) and nuclear factor of activated T-cells (NFAT) [107].
Very recently, in human aortic endothelial cells (HAEC) vascular
endothelial growth factor receptor 2 (VEGFR2) was reported to
be a major regulator in the ERK1/2-mediated activation of the
transcription factor sterol regulatory element-binding protein 1
(SREBP-1) and subsequent transcription of TF, LDL receptor and
IL-8 [108]. In addition, this study revealed PEI-PC to be the active
component of oxPA-PC-mediated activation of this signaling
pathway. Furthermore, induction of chemotactic activity of
monocytes via activation of MAPK phosphatase 1 was
demonstrated as well as expression of numerous inflammatory
genes [109,110]. Very recently, POV-PC was found to activate
cPLA2 via theMAPK pathway in HUVEC resulting in the release
of free AA [111]. The latter is subsequently used by lipoxygenase
but not cyclooxygenase, producing 12-HETE that previously has
been shown to stimulateHAEC to bindmonocytes [112]. Possible
targets for HETEs are the lipid-dependent transcription factors
peroxisome proliferator-activated receptor α and γ (PPARα ,
PPARγ). Indeed, both have been reported to become activated by
the products of phospholipid oxidation. PEI-PC and PEC-PC
isomers, which are both found in oxPA-PC increase IL-8 and
monocyte chemotactic protein-1 (MCP-1) expression in endo-
thelial cells involving activation of PPARα [113,114]. However,
although PPARα-null murine aortic endothelial cells did not
produce MCP-1/JE in response to oxPA-PC [113], a role for
PPARα in oxPA-PC induction of IL-8 transcription in HAEC
could not be consistently demonstrated [115]. Importantly, the
increase of IL-8 and MCP-1 expression induced by oxidized
phospholipids was independent of the classical NF-κB pathway,
but involved the activation of c-Src kinase. PEI-PC binds to the
TLR4 complex and leads to rapid and transient activation of c-Src
kinase that in turn induces phosphorylation and activation of the
transcription factor signal transducer and activator of transcription
3 (STAT3) [116]. Subsequently, STAT3 dimerizes, translocates to
the nucleus and induces transcription of IL-8. Recently, HDLwas
reported to inhibit oxidized phospholipid-induced c-Src/STAT3
and SREBP activation as well as endothelial nitric oxide synthase
phosphorylation [117] that was previously also associated with
the inflammatory effects of oxPA-PC [118]. Interestingly, HDL
did not interfere with oxPA-PC-induced expression of antioxidant
proteins such as heme oxygenase 1 (HO-1) or the heat-shock
protein A1A via the transcription factor NF-E2-related factor-2
(Nrf2) [117]. Thus, high-density lipoprotein (HDL) not only
inhibits the pro-inflammatory effects of oxidized phospholipidssuch as PEI-PC, but also maintains the antioxidant cellular
responses to these oxidized lipids.
The oxidized fatty acids 9-HODE and 13-HODE that have
also been found in oxLDL were both reported to be activators
and ligands of PPAR γ, thereby inducing CD36 scavenger
receptors and foam cell formation [119]. Others found that POV-
PC also binds to human macrophages via the PAF-receptor
followed by stimulation of intracellular calcium signaling which
activates the transcription of highly proinflammatory cytokines
such as IL-8 [87].
Hydroxy and oxo alkenal phospholipids such as HOOA-PC,
KOOA-PC, KOdiA-PC and HOdiA-PC are another group of
oxidized phospholipids found in LDL in vivo and are enriched in
atherosclerotic lesions [83]. These compounds localize to the
surface of oxidized LDL and represent ligands of CD36 on
macrophages (see also Section 3). Lipid binding to the receptor
is responsible for uptake of the whole particle, intracellular
accumulation of cholesterol and foam cell formation [8,83].
HOOA-PC also activates endothelial binding of monocytes,
increases formation of MCP-1 and IL-8 [120]. Furthermore, it
was shown that various pure hydroxy alkenal phospholipids like
KHdiA-PE, KOdiA-PE, KDdiA-PE, HDdiA-PE or HOOA-PC
potently inhibit LPS-induced inflammation and thus mimic the
actions of oxPA-PE or oxPA-PC [120–122]. KOdiA-PC was the
most potent compound inhibiting LPS-induced expression of E-
selectin 500-fold more than oxPA-PC. Very recently, it has been
shown that this inhibitory effect of KOdiA-PC on LPS induction
of IL-8 is mediated, at least in part, by the activation of neutral
sphingomyelinase and its product ceramide might induce
changes in the assembly of the LPS receptor complex [122].
Furthermore, it was found that there is some overlap in gene
expression induced by LPS and oxPA-PC. But it is noteworthy
that there are also significant differences [123]. Genes induced
by LPS and oxidized phospholipids (oxPA-PC) include IL-6, IL-
8, IP-10, and MCP-1. In addition, γ-hydroxyalkenal PCs inhibit
a key function of macrophages, namely the processing of
internalized material. These compounds reduce cathepsin B
activity and the maturation of the fusion protein Rab5a, leading
to reduced endosome–phagosome fusion with lysosomes in
mouse peritoneal macrophages [7].
In addition to oxidized diacylglycerophospholipids, oxidized
alkylacylglycero-phospholipids mimic PAF which is one of the
most potent inflammatory mediator [124]. In general, these PAF-
like lipids activate leukocytes and can stimulate the growth of
smooth muscle cells [125], which is inhibited by a PAF-R an-
tagonist. Furthermore, PAF-like lipids stimulate polymorphonu-
clear leukocyte adhesion to endothelial cells followed by activation
of intracellular calcium fluxes [126]. Activation of platelets and
stimulation ofγ-interferon secretion fromhumanmonocytes is also
mediated by the PAF-Rs [3]. Another oxidatively fragmented
alkylacylglycerophospholipid of oxLDL is HAz-PC. It is a very
potent PPARγ agonist [29], induces cyclooxygenase-2 expression
and stimulates prostaglandin E2 secretion in primary human
monocytes [127].
In addition to the biological effects of pure oxidized
phospholipids, there is a plethora of effects of oxidized
phospholipidsmixtures, ofwhich themost relevant are summarized
Table 2
Biological effects of selected pure oxidized phospholipids and oxPA-PC in macrophages, endothelial cells and smooth muscle cells
Effects in macrophages Effects in endothelial cells Effects in smooth muscle cells Other effects
POV-PC
Blocked uptake of oxLDL [98] Induction of monocyte binding and inhibition of
neutrophil binding [103]
Induction of apoptotic pathways, including SMase,
p38-MAPK, JNK and caspases [47,139]
Recognized by monoclonal
antibodies [19]
Binding to PAF-R and transduction of the signals
leading to the intracellular Ca2+ fluxes and
modification of the transcription levels of numerous
pro-inflammatory and pro-atherogenic genes [87]
Specific monocyte binding involves activation
of cPLA2 and lipoxygenase [111]
Stimulation of UDP-galactose: glucosylceramide
(β1–4) galactosyl transferase, production of
lactosylceramide and activation of p44-MAPK
and proliferation [150]
Upregulation of CS-1 fibronectin expression [48]
Generation of angiogenic mediators via VEGF and
COX-2-generated prostanoids [149]
PG-PC
Induction of monocyte and neutrophil binding,
E-Selectin-expression [103]
Induction of apoptotic pathways, including
sphingomyelinases, p38-MAPK, JNK and
caspases [47,139]Upregulation of VCAM-1 [48]
Generation of angiogenic mediators via VEGF and
COX-2-generated prostanoids [149]
PEI-PC
Induction of monocyte/endothelial cell adhesion via
activation of cAMP/R-Ras/PI3-K signaling pathway [105]
Restoration of endothelial
barrier function via
Cdc42 and Rac [151]Regulation of MCP-1 and IL-8 synthesis via the c-Src/
STAT3 pathway [114,115]
Activation of TF and SREBP-1 via VEGFR2 [108]
Activates PPARα in murine aortic endothelial cells [113]
PEC-PC
Activates PPARα, increases IL-1 and MCP-1 synthesis [114]
KOdiA-PC, HOdiA-PC, KOOA-PC, HOOA-PC
Ligands for CD36 [8,83] HOOA-PC activates endothelial cells to bind monocytes,
causes an increase in MCP-1 and IL-8Inhibit the processing of internalized material,
reduce cathepsin B activity and the maturation
of the fusion protein Rab5a [7]
Inhibition of LPS-induced expression of E-Selectin [120]
via activation of neutral sphingomyelinase [122]
PAF-like lipids
Stimulation of γ-interferon secretion from human
monocytes via their PAF-R [3]
Growth stimulation [125] Stimulate polymorphonuclear
leukocyte adhesion [126]Regulation of DNA synthesis and NO
production [140] Activate platelets through
their PAF-R [3]
Induction of apoptosis by temporary
membrane distortions [141]
(continued on next page)
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Table 2 (continued)
Effects in macrophages Effects in endothelial cells Effects in smooth muscle cells Other effects
Az-PC
Potent PPARγ agonist [29]
Induction of cyclooxygenase-2 expression and
enhanced prostaglandin E2 secretion in primary
human monocytes [127]
9- and 13-HODE
Activators and ligands of PPARγ, leading to the
induction of CD36 and foam cell formation [119]
15(S)-HPETE
Induction of apoptosis [142]
oxPA-PC (additional effects only studied as a
complex mixture)
Blocked uptake of oxLDL [98] Microarray analysis revealed changes in N1000 genes [128] Recognized by monoclonal
antibodies [19]Inhibition of cyclooxygenase-2 via NF-κB/IκB and
ERK2-dependent mechanisms [110,152]
Induction of monocyte chemotactic activity via
activation of MAPK phosphatase 1 [109] Induction of murine MCP-1
homologue JE) in liver and
heart [123]
Activation of MCP-1 and IL-8 synthesis [114,123]
Upregulation of CD62p and
CD41 receptors and
inhibition of anti-CD36
MoAb binding in
platelets [157]
Depletion of endothelial cholesterol (causing caveolin-1
internalization from the plasma membrane to
the ER and Golgi) and activation of SREBP [108,153]
Induction of atherosclerosis-
related genes in murine
arteries [158]
Induction of genes involved in signal transduction, extracellular
matrix, growth factors and chemokines [110]
Stimulation of tissue factor expression via activation of
ERK/EGR-1 and Ca2+/NFAT [107]
Activation of PKC, PKA, Raf/MEK1,2/ERK-1,2 MAP
kinase cascade, JNK Map kinase and transient
protein tyrosine phosphorylation [154]
Induction of heme oxygenase-1 expression involving
activation of CREBP [155]
Down-regulation of thrombomodulin transcription by inhibiting the
binding of RARβ-RXRα heterodimer and stimulatory proteins
(Sp1 and Sp3) to the DR4 and Sp1 binding element
in the TM promoter and reduced expression of RARβ,
RXRα and SP1 and SP3 in the nucleus [156]
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approach that more than 1000 genes were regulated by oxidized
phospholipids (oxPA-PC) in HAEC cultures derived from 12
individuals [128]. However, we will not discuss all biological
effects of these oxidized phospholipids mixtures in detail, since it is
difficult to interpret effects of mixtures on a molecular basis. Thus,
it would be desirable to put more emphasis on the biological effects
of pure compounds and perform future studies using chemically
well-defined oxidized phospholipids.
4.2. Oxidized phospholipids, apoptosis and apoptotic signaling
Increasing evidence suggests that apoptosis is a major event
in the pathology of atherosclerosis [129]. In primary and
secondary lesions apoptosis may help to reduce lesion size
[130,131], whereas at later stages apoptosis may contribute to
the formation of unstable plaques [132,133].
On the other hand, apoptotic cells are an additional source of
oxidized phospholipids and may actively contribute to inflam-
mation [134]. Apoptosis of endothelial cells is associated with
oxidation of PC, PS, and PE [135]. Oxidized PC on the surface
of apoptotic cells was detected using the monoclonal antibody
EO6, which exclusively binds to protein-bound oxidized PC
[101]. It has been shown that EO6 can effectively block the
uptake of apoptotic cells by macrophages. Thus, in addition to
oxidized PS, the presence of oxidatively modified PC is an
important signal for phagocytosis and externalization of oxi-
dized phospholipids was shown to be required for macrophage
clearance of apoptotic cells [136]. Blebs from apoptotic
endothelial cells and biologically active oxidized membrane
vesicles contain POV-PC and activate endothelial cells to bind
monocytes but not neutrophils [134]. The ability of apoptotic
blebs or oxidized vesicles to induce monocyte adhesion was
abolished by preincubation with the EO6 antibody recognizing
oxidized PC [134]. Lipid peroxidation of biological membranes
also leads to the loss of phospholipid asymmetry in plasma
membranes of apoptotic cells and causes membrane vesicula-
tion. Microvesicles released from endothelial cells under the
influence of tert-butylhydroperoxide in vitro contained the ox-
idized phospholipids POV-PC and PG-PC [137] and induced
monocyte–endothelial interactions [134]. In contrast, mem-
brane vesicles from activated endothelial cells failed to bind
monocytes [134]. Recently, it was shown that apoptotic blebs
derived from T-cells also contain oxidized phospholipids and
thus induce monocyte–endothelial interactions [138].
As described above, apoptotic cells can be the source for
oxidized phospholipids, but in addition, oxidized phospholipids
themselves can induce apoptosis of the cells of the vascular wall.
It was shown in our laboratory, that PG-PC and POV-PC
activate sphingomyelinases in arterial smooth muscle cells. The
sphingolipid-hydrolyzing enzyme is known to participate in the
very early phase of stress signaling. Downstream of acid
sphingomyelinase (aSMase) the mitogen-activated protein
kinases (MAPK) c-Jun N-terminal kinase (JNK) and p38 which
are also involved in induction of stress response and apoptosis
were phosphorylated. Further downstream of JNK and p38
MAPK activation of caspase 3 was observed, showing thatstimulation of smooth muscle cells with POV-PC and PG-PCwas
associated with apoptosis [139]. Stimulation of all these enzymes
by POV-PC and PG-PC almost perfectly matched the activation
of intracellular signaling bymmLDL in the same cells. Obviously,
oxidized phospholipids are responsible for the effects of this
lipoprotein on apoptotic signaling. In contrast, components of
survival and proliferation pathways including NF-κB or AKT-
kinase were not activated by POV-PC and PG-PC. Experiments
withNB6, which specifically inhibits gene expression of aSMase,
showed that this enzyme plays a central role in mediating the
apoptotic effects of POV-PC and PG-PC. In addition, oxidized
phospholipid-induced apoptosis of arterial smooth muscle cells
was also assessed by determining several morphological criteria,
the occurrence of DNA fragmentation, and a PS shift towards the
outer leaflet of the plasma membrane [47]. In all experiments
POV-PC was a more potent apoptotic agent than PG-PC.
Furthermore, PAF-like lipids can regulate DNA synthesis
and nitric oxide production without involvement of the PAF-R
in vascular smooth muscle cells [140]. Thus, these compounds
seem to be able to induce apoptosis of vascular smooth muscle
cells also by temporary membrane distortions [141].
Moreover, AA and its oxidation products HPETE, 15(S)-
HPETE, HNE and MDAwere also shown to induce apoptosis of
vascular smooth muscle cells. The apoptotic effects are charac-
terized by annexin V binding, sub-G1 population of cells, cell
shrinkage and chromatin condensation. Vascular smooth muscle
cells death was attenuated by the antioxidants α-tocopherol and
glutathione, the hydrogen peroxide scavenger catalase and the
serum proteins albumin and gamma globulin [142].
5. Future perspectives
So far, many studies on oxidized phospholipids have been
performed usingmixtures of oxidation products that are generated
from their polyunsaturated parent compounds, e.g. PA-PC. These
preparations contain a large variety of different substances
differing in structure, polarity and hydrophobicity. As a con-
sequence, the biological availability, the degree of polarity and
amphiphilicity, as well as the reactivities of the individual lipid
classes contribute to the observed effects of “oxidized phospho-
lipids” to a greatly different extent. Although in the past years
various research groups became interested in the effects of pure
oxidized phospholipids rather than complex mixtures, many
biological effects are not fully understood or remain unclear.
Thus, it will be desirable to concentrate on chemically defined
lipid species in the future. In addition, it is mandatory to specify
how these compounds are presented to a cell or an individual
target molecule. Even the truncated phospholipids are still
hydrophobic enough to bind efficiently to lipoproteins, cell
membranes or proteins (albumin!). However, their diffusion rates
and thus their bioavailabilities are higher as compared to the more
hydrophobic dual-chain lipids. Since their action radius is much
larger, they do not only act locally in a cell but may also transmit
signals within a larger cross section of a tissue. This high
exchangeability and mobility challenges the concept of lipid
interaction with specific cell surface receptors. This phenomenon
is particularly relevant to the more polar oxidized phospholipids.
732 G.O. Fruhwirth et al. / Biochimica et Biophysica Acta 1772 (2007) 718–736After they have been generated within a cell or a lipoprotein they
may interact with many different target proteins and lipids on the
surface of and inside a cell leading to impaired functions of these
target molecules. We recently showed that fluorescent analogs of
oxidized phospholipids are easily taken up into cells and label a
limited fraction of their proteins and lipids [143]. The
identification of these target molecules and their downstream
effectors will be an important issue in the future, which will help
to understand the complex molecular network underlying the
biological effects of oxidized phospholipids.
Amajor focus of current biomedical studies is still on the role of
these compounds in classical lipid-associated disorders including
atherosclerosis. Other fields such as cancer research and immu-
nology will be emerging in the context of oxidative stress and the
role of oxidized lipids in the initiation and progress of related
diseases. The interdependence of cell growth, (programmed) cell
death and cell function is a key aspect in the context of (patho)
physiological lipid activity. Thus, it can be expected that research
on the great variety of oxidized phospholipid species will not only
lead to a deeper understanding of these compounds but will also
provide new insights into the function of lipid mediators.
6. Abbreviations of chemical nomenclature
AA arachidonic acid
DP-PC 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine
G-PC and ND-PC glutaric and nonanedioic monoesters of LPC
HAz-PC 1-O-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine
HDdiA-PC and HOdiA-PC 9-hydroxy-10-dodecenedioic acidand 5-hydroxy-8-oxo-6-octenedioic acid esters of LPC
HETE hydroxyeicosatetraenoic acid (position of hydroxyl group
not specified)
HNE 4-hydroxy-trans-2-nonenal
HODA-PC and HOOA-PC 9-hydroxy-12-oxo-10-dodecenoicacid and 5-hydroxy-8-oxo-6-octenoic acid esters of LPC
HODE hydroxyoctadecanoic acid (position of hydroxyl group
not specified)
HPODE hydroperoxyoctadecadienoic acid (position of hydroxyl
group not specified)
KDdiA-PC and KOdiA-PC 9-keto-10-dodecendioic acid and5-keto-6-octendioic acid esters of LPC
KHdiA-PE 3-keto-4-hexendioic acid esters of LPE
KODA-PC and KOOA-PC 9-keto-12-oxo-10-dodecenoic acidand 5-keto-8-oxo-6-octenoic acid esters of LPC
LA linoleic acid
LDL low density lipoprotein
LPC 1-acyl-sn-glycero-3-phosphocholine (1-acyl group not
specified)
LPE 1-acyl-sn-glycero-3-phosphoethanolamine (1-acyl group
not specified)
LP-PC 1-hexadecadienoyl-2-hexadecanoyl-sn-glycero-3-
phosphocholine
MDA malondialdehyde
mmLDL minimally modified LDL
OV-PC and ON-PC 5-oxovaleric acid and 9-oxononanoic acidesters of LPCoxLDL oxidized LDL
oxPA-PC, oxPA-PS, oxPA-PE undefined mixtures of freeradically-oxidized PA-PC, PA-PS, PA-PE
PAF platelet-activating factor, 1-O-alkyl-2-acetyl-sn-glycero-
3-phosphocholine
PA-PC 1-hexadecanoyl-2-eicosatetra-5′,8′,11′,14′-enoyl-sn-
glycero-3-phosphocholine
Paz-PC 1-hexadecanoyl-2-azelaoyl-sn-glycero-3-phosphocholine
PC phosphatidylcholine
PE phosphatidylethanolamine
PEC-PC 1-hexadecanoyl-2-(5,6-epoxyisoprostane A2 oyl)-sn-
glycero-3-phosphocholine
PEI-PC 1-hexadecanoyl-2-(5,6-epoxyisoprostane E2 oyl)-sn-
glycero-3-phosphocholine
PI phosphatidylinositol
PL-PC 1-hexadecanoyl-2-octadecadi-9′,12′-enoyl-sn-glycero-
3-phosphocholine
PON-PC1-hexadecanoyl-2-(9′-oxononanoyl)-sn-glycero-3-
phosphocholine
POV-PC, PON-PC, PG-PC and PND-PC 1-acyl group is ahexadecanoic acid ester of OV-PC, ON-PC, G-PC and
ND-PCPS phosphatidylserine
Acknowledgements
This work was supported by the Austrian Science Fund
(project numbers P14714-PHA and SFB Lipotox F30-B05).
References
[1] B. Gugiu, C. Mesaros, M. Sun, X. Gu, J.W. Crabb, R.G. Salomon,
Identification of oxidatively truncated ethanolamine phospholipids in
retina and their generation from polyunsaturated phosphatidylethanola-
mines, Chem. Res. Toxicol. 19 (2006) 262–271.
[2] T. Matsura, A. Togawa, M. Kai, T. Nishida, J. Nakada, Y. Ishibe, S. Kojo,
Y. Yamamoto, K. Yamada, The presence of oxidized phosphatidylserine
on Fas-mediated apoptotic cell surface, Biochim. Biophys. Acta (BBA)—
Mol. Cell Biol. Lipids 1736 (2005) 181–188.
[3] T.M. McIntyre, G.A. Zimmerman, S.M. Prescott, Biologically active
oxidized phospholipids, J. Biol. Chem. 274 (1999) 25189–25192.
[4] D.B. Min, Lipid Oxidation of Edible Oil, in: C.C. Akoh, D.B. Min (Eds.),
Food Lipids — Chemistry, Nutrition, and Biotechnology, Food Science
in Technology, Marcel Dekker Inc., New York, 1997, pp. 283–296.
[5] G. Spiteller, Is atherosclerosis a multifactorial disease or is it induced by a
sequence of lipid peroxidation reactions? Ann. N.Y. Acad. Sci. 1043
(2005) 355–366.
[6] D.M. Stafforini, J.R. Sheller, T.S. Blackwell, A. Sapirstein, F.E. Yull, T.M.
McIntyre, J.V. Bonventre, S.M. Prescott, L.J. Roberts, Release of free F2-
isoprostanes from esterified phospholipids is catalyzed by intracellular
and plasma platelet-activating factor acetylhydrolases, J. Biol. Chem. 281
(2006) 4616–4623.
[7] H.F. Hoff, J. O'Neil, Z. Wu, G. Hoppe, R.L. Salomon, Phospholipid
hydroxyalkenals: biological and chemical properties of specific oxidized
lipids present in atherosclerotic lesions, Arterioscler. Thromb. Vasc. Biol.
23 (2003) 275–282.
[8] E.A. Podrez, E. Poliakov, Z. Shen, R. Zhang, Y. Deng,M. Sun, P.J. Finton,
L. Shan, B. Gugiu, P.L. Fox, H.F. Hoff, R.G. Salomon, S.L. Hazen,
Identification of a novel family of oxidized phospholipids that serve as
ligands for the macrophage scavenger receptor CD36, J. Biol. Chem. 277
(2002) 38503–38516.
733G.O. Fruhwirth et al. / Biochimica et Biophysica Acta 1772 (2007) 718–736[9] R.J. Schaur, Basic aspects of the biochemical reactivity of 4-hydroxynonenal,
Mol. Aspects Med. 24 (2003) 149–159.
[10] S. Gao, R. Zhang, M.E. Greenberg, M. Sun, X. Chen, B.S. Levison, R.G.
Salomon, S.L. Hazen, Phospholipid hydroxyalkenals, a subset of recently
discovered endogenous CD36 ligands, spontaneously generate novel
furan-containing phospholipids lacking CD36 binding activity in vivo,
J. Biol. Chem. 281 (2006) 31298–31308.
[11] J.D. Morrow, J.A. Awad, H.J. Boss, I.A. Blair, L.J. Roberts, Non-
cyclooxygenase-derived prostanoids (F2-Isoprostanes) are formed in situ
on phospholipids, PNAS 89 (1992) 10721–10725.
[12] J.D. Morrow, L.J. Roberts, Lipid-Derived Autocoids: Eicosanoids and
Platelet Activating Factor, in: J.G. Hardman, L.E. Limbird (Eds.),
Goodman's and Gilman's The pharmacological Basis of Therapeutics,
McGraw-Hill, New York, 2001, pp. 669–687.
[13] R.J. Waugh, J.D. Morrow, L.J. Roberts, Murphhy, Identification and
relative quantitation of F2-isoprostane regioisomers formed in vivo in the
rat, Free Radic. Biol. Med. 23 (1997) 943–954.
[14] H. Yin, N.A. Porter, J.D. Morrow, Separation and identification of F2-
isoprostane regioisomers and diastereomers by novel liquid chromatograph-
ic/mass spectrometric methods, J. Chromatogr., A 827 (2005) 157–164.
[15] T.J. Montine, K.S. Montine, E.E. Reich, E.S. Terry, N.A. Porter, J.D.
Morrow, Antioxidant significantly affect the formation of different
classes of isoprostanes and neuroprostanes in rat cerebral synaptosomes,
Biochem. Pharmacol. 65 (2003) 611–617.
[16] Y. Chen, J.D. Morrow, L.J. Roberts II, Formation of reactive cyclopente-
none compounds in vivo as products of the isoprostane pathway, J. Biol.
Chem. 274 (1999) 10863–10868.
[17] G.L. Milne, L. Gao, L. Zanoni, G. Vidari, J.D. Morrow, Identification
of the major urinary metabolite of the highly reactive cyclopente-
none isoprostane 15-A2t-Isoprostane in vivo, J. Biol. Chem. 280 (2005)
25178–25184.
[18] H.W. Gardner, Oxygen radical chemistry of polyunsaturated fatty acids,
Free Radic. Biol. Med. 7 (1989) 65–86.
[19] A.D. Watson, G. Subbanagounder, D.S. Welsbie, K.F. Faull, M. Navab,
M.E. Jung, A.M. Fogelman, J.A. Berliner, Structural identification of a
novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxi-
dized low density lipoprotein, J. Biol. Chem. 274 (1999) 24787–24798.
[20] L. Gao, W.E. Zackert, J.J. Hasford, M.E. Danekis, G.L. Milne, C.
Remmert, J. Reese, H. Yin, H.H. Tai, S.K. Dey, N.A. Porter, J.D. Morrow,
Formation of prostaglandins E2 and D2 via the isoprostane pathway: a
mechanism for the generation of bioactive prostaglandins independent of
cyclooxygenase, J. Biol. Chem. 278 (2003) 28479–28489.
[21] R.G. Salomon, D.B. Miller, M. Zagorski, D.J. Coughlin, Solvent-induced
fragmentation of prostaglandin endoperoxides. New aldehyde products
from PGH2 and a novel intramolecular 1,2-hydride shift during
endoperoxide fragmentation in aqueous solution, J. Am. Chem. Soc. 106
(1984) 6049–6060.
[22] R.G. Salomon, G. Subbanagounder, U. Singh, J. O'Neil, H.F. Hoff,
Oxidation of low-density lipoproteins produces levuglandin-protein
adducts, Chem. Res. Toxicol. 10 (1997) 750–759.
[23] O. Boutaud, C.J. Brame, R.G. Salomon, L.J. Roberts, J.A. Oates,
Characterization of the lysyl adducts formed from prostaglandin H2 via
the levuglandin pathway, Biochemistry (Moscow) 38 (1999) 9389–9396.
[24] R.S. Iyer, M.E. Kobierski, R.G. Salomon, Generation of pyrroles in the
reaction of Levuglandin E2 with proteins, J. Org. Chem. 59 (1994)
6038–6043.
[25] C.J. Brame, R.G. Salomon, J.D. Morrow, L.J. Roberts II, Identification of
extremely reactive gamma-ketoaldehydes (isolevuglandins) as products
of the isoprostane pathway and characterization of their lysyl protein
adducts, J. Biol. Chem. 274 (1999) 13139–13146.
[26] E. Poliakov, S.G. Meer, S.C. Roy, C. Mesaros, R.G. Salomon, Iso[7]
LGD2-protein adducts are abundant in vivo and free radical-induced
oxidation of an arachidonyl phospholipid generates this D series
isolevuglandin in vitro, Chem. Res. Toxicol. 17 (2004) 613–622.
[27] Animal longevity and protein turnover rate, Nature 249 (1974) 66–67.
[28] G.K. Marathe, S.S. Davies, A. Harrison, A.R. Silva, R.C. Murphy, H.
Castro-Faria-Neto, S.M. Prescott, G. Zimmerman, T.M. McIntyre,
Inflammatory platelet-activating factor-like phospholipids in oxidizedlow density lipoproteins are fragmented alkyl phosphatidylcholines,
J. Biol. Chem. 274 (1999) 28395–28404.
[29] S.S. Davies, A.V. Ponstler, G.K. Marathe, K.A. Harrision, R.C. Murphy,
J.C. Hinshaw, G.D. Prestwich, A.S. Hilaire, S.M. Prescott, G. Zimmer-
man, T.M. McIntyre, Oxidized alkyl phospholipids are specific, high
affinity peroxisome proliferator-activated receptor ligands and agonists,
J. Biol. Chem. 276 (2001) 16015–16023.
[30] N. Khaselev, R.C. Murphy, Structural characterization of oxidized
phospholipid products derived from arachidonate-containing plasmenyl
glycerophosphocholine, J. Lipid Res. 41 (2000) 564–572.
[31] N. Janes, Curvature stress and polymorphism in membranes, Chem. Phys.
Lipids 81 (1996) 133–150.
[32] J.W. Borst, N.V. Visser, O. Kouptsova, A.J.W.G. Visser, Oxidation of
unsaturated phospholipids in membrane bilayer mixtures is accompanied
by membrane fluidity changes, Biochim. Biophys. Acta (BBA) — Mol.
Cell Biol. Lipids 1487 (2000) 61–73.
[33] E.H.W. Pap, A. Hanicak, A. van Hoek, K.W.A. Wirtz, A.J.W.G. Visser,
Quantitative analysis of lipid–lipid and lipid–protein interactions in
membranes by use of pyrene-labeled phosphoinositides, Biochemistry
(Moscow) 34 (1995) 9118–9125.
[34] F.M. Megli, L. Russo, K. Sabatini, Oxidized phospholipids induce phase
separation in lipid vesicles, FEBS Lett. 579 (2005) 4577–4584.
[35] K. Sabatini, J.P. Mattila, F.M. Megli, P.K. Kinnunen, Characterization of
two oxidatively modified phospholipids in mixed monolayers with
DPPC, Biophys. J. 90 (2006) 4488–4499.
[36] F.M. Megli, K. Sabatini, Respiration state IV-generated ROS destroy the
mitochondrial bilayer packing order in vitro. An EPR study, FEBS Lett.
550 (2003) 185–189.
[37] F.M. Megli, K. Sabatini, Mitochondrial phospholipid bilayer structure is
ruined after liver oxidative injury in vivo, FEBS Lett. 573 (2004) 68–72.
[38] P.K.J. Kinnunen, On the principles of functional ordering in biological
membranes, Chem. Phys. Lipids 57 (1991) 375–399.
[39] P.K.J. Kinnunen, Lipid bilayers as osmotic response elements, Cell.
Physiol. Biochem. 10 (2000) 234–250.
[40] S. Chakraborti, Phospholipase A2 isoforms: a perspective, Cell. Signal.
15 (2003) 637–665.
[41] K. Karasawa, Clinical aspects of plasma platelet-activating factor-
acetylhydrolase, Biochim. Biophys. Acta (BBA) — Mol. Cell Biol.
Lipids 1761 (2006) 1359–1372.
[42] K.L. Carpenter, I.R. Challis, M.J. Arends, Mildly oxidised LDL induces
more macrophage death than moderately oxidised LDL: roles of
peroxidation, lipoprotein-associated phospholipase A2 and PPARα, FEBS
Lett. 553 (2003) 145–150.
[43] K.L. Carpenter, I.F. Dennis, I.R. Challis, D.P. Osorn, C.H. Macphee, D.S.
Leake, M.J. Arends, M.J. Mitchinson, Inhibition of lipoprotein-associated
phospholipase A2 diminishes the death-inducing effects of oxidised LDL
on human monocyte-macrophages, FEBS Lett. 505 (2001) 357–363.
[44] M. Benson, D. grimsditch, K. Milliner, K. Moores, H.F. Boyd, D. Tew, D.
Hickey, R. Ife, K. Suckling, C.H. Macphee, Anti-atherosclerotic effect of
SB-244323, a lipoprotein associated phospholipase A2 inhibitor, in
WHHL rabbits, Atherosclerosis 151 (2000) 166–167.
[45] M. Persson, J.A. Nilsson, J.J. Nelson, B. Hedblad, G. Berglund, The
epidemiology of Lp-PLA2: distribution and correlation with cardiovascular
risk factors in a population-based cohort,Atherosclerosis 190 (2007) 388–396.
[46] A. Matsuzawa, K. Hattori, J. Aoki, H. Arai, K. Inoue, Protection against
oxidative stress-induced cell death by intracellular platelet-activating
factor-acetylhydrolase II, J. Biol. Chem. 272 (1997) 32315–32320.
[47] G.O. Fruhwirth, A. Moumtzi, A. Loidl, E. Ingolic, A. Hermetter, The
oxidized phospholipids POVPC and PGPC inhibit growth and induce
apoptosis in vascular smooth muscle cells, Biochim. Biophys. Acta 1761
(2006) 1060–1069.
[48] G. Subbanagounder, N. Leitinger, D.C. Schwenke, J.W. Wong, H. Lee, C.
Rizza, A.D. Watson, K.F. Faull, A.M. Fogelman, J.A. Berliner, Determinants
of bioactivity of oxidized phospholipids: specific oxidized fatty acyl groups at
the sn-2 position, Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2248–2254.
[49] A.D. Tselepis, M.J. Chapmann, Inflammation, bioactive lipids and athero-
sclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet
activating factor-acetylhydrolase, Atherosclerosis 3 (2002) 57–68.
734 G.O. Fruhwirth et al. / Biochimica et Biophysica Acta 1772 (2007) 718–736[50] S. Miyamoto, C. Dupas, K. Murota, J. Terao, Phospholipid hydroper-
oxides are detoxified by phospholipase A2 and GSH peroxidase in rat
gastric mucosa, Lipids 38 (2003) 641–649.
[51] D.R. Moellering, A.L. Levonen, Y.M. Go, R. Patel, D.A. Dickinson, H.J.
Forman, V.M. Darley-usmar, Induction of glutathione synthesis by
oxidized low-density lipoprotein and 1-palmitoyl-2-arachidonoyl phos-
phatidylcholine: protection against quinone-mediated oxidative stress,
Biochem. J. 362 (2002) 51–59.
[52] R. Brigelius-Flohé, S. Maurer, K. Lötzer, G.-F. Böl, H. Kallionpää, P.
Lehtolainen, H. Viita, S. Ylä-Herttuala, Overexpression of PHGPx
inhibits hydroperoxide-induced oxidation, NFκB activation and apopto-
sis and affects oxLDL-mediated proliferation of rabbit aortic smooth
muscle cells, Atherosclerosis 152 (2000) 307–316.
[53] H. Imai, Y. Nakagawa, Biological significance of phospholipid hydro-
peroxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells,
Free Radic. Biol. Med. 34 (2003) 145–169.
[54] Y. Shidoji, K. Okamoto, Y. Muto, S. Komura, N. Ohishi, K. Yagi,
Prevention of geranylgeranoic acid-induced apoptosis by phospholipid
hydroperoxide glutathione peroxidase gene, J. Cell Biochem. 97 (1)
(2006) 178–187.
[55] S.K. Srivastava, S.Q. Liu, D.J. Conklin, A. Zacarias, S.K. Srivastava, A.
Bhatnagar, Involvement of aldose reductase in the metabolism of
atherogenic aldehydes, Chem. Biol. Interact. 130–132 (2001) 563–571.
[56] S.K. Srivastava, M. Spite, J.O. Trent, M.B. West, Y. Ahmed, A.
Bhatnagar, Aldose reductase-catalysed reduction of aldehyde phospho-
lipids, J. Biol. Chem. 279 (2004) 53395–53406.
[57] J. Alary, F. Bravais, J.P. Cravedi, L. Debrauwer, D. Rao, G. Bories,
Mercapturic acid conjugates as urinary end metabolites of the lipid
peroxidation product 4-hydoxy-2-nonenal in the rat, Chem. Res. Toxicol.
8 (1995) 34–39.
[58] K. Kaur, R.G. Salomon, J. O'Neil, H.F. Hoff, (Carboxyalkyl)pyrroles in
human plasma and oxidized low-density lipoproteins, Chem. Res.
Toxicol. 10 (1997) 1387–1396.
[59] R.G. Salomon, K. Kaur, E.A. Podrez, H.F. Hoff, A.V. Krushinsky, L.M.
Sayre, HNE-derived 2-pentylpyrroles are generated during oxidation of
LDL, are more prevalent in blood plasma from patients with renal disease
or atherosclerosis, and are present in atherosclerotic plaques, Chem. Res.
Toxicol. 13 (2000) 557–564.
[60] M. Guichardant, P. Taibi-Tronche, L.F. Fay, M. lagarde, Covalent
modifications of aminophospholipids by 4-hydroxynonenal, Free Radic.
Biol. Med. 25 (1998) 1049–1056.
[61] M. Wacker, P. Wanek, E. Eder, Detection of 1,N-2-propanedeoxyguano-
sine adducts of trans-4-hydroxy-2-nonenal after gavage of trans-4-
hydroxy-2-nonenal or induction of lipid peroxidation with carbon-
tetrachloride in F344 rats, Chem. Biol. Interact. 130 (2001) 261–273.
[62] H.J.C. Chen, F.J. Gonzalez, M.G. Shou, F.L. CHung, 2,3-Epoxy-4-
hydroxynonenal, a potential lipid peroxidation product for etheno adduct
formation, is not a substrate of human epoxide hydrolase, Carcinogenesis
19 (1998) 939–943.
[63] R.S. Iyer, S. Ghosh, R.G. Salomon, Levuglandin E2 crosslinks proteins,
Prostaglandins 37 (1989) 471–480.
[64] O. Boutaud, J.J. Ou, P. Chautrand, R.M. Caprioli, T.J. Montine, J.A.
Oates, Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1–
42 oligomers, J. Neurochem. 82 (2002) 1003–1006.
[65] S.S. Davies, V. Amarnath, K.S. Montine, N. Bernoud-Hubac, O. Boutaud,
T.J. Montine, L.J. Roberts, Effects of reactive {gamma}-ketoaldehydes
formed by the isoprostane pathway (isoketals) and cyclooxygenase
pathway (levuglandins) on proteasome function, FASEB J. 16 (2002)
715–717.
[66] R. Medzhitov, Toll-like receptors and innate immunity, Nat. Immun. 1
(2001) 135–145.
[67] K.A. Walton, X. Hsieh, N. Gharavi, S. Wang, G. Wang, M. Yeh, A.L.
Cole, J.A. Berliner, Receptors involved in the oxidized 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of in-
terleukin-8: a role for toll-like receptor 4 and a glycophosphatidylinositol-
anchored protein, J. Biol. Chem. 278 (2003) 29661–29666.
[68] M.K. Chang, C.J. Binder, M. Torzewski, J.L. Witztum, C-reactive protein
binds to both oxidized LDL and apoptotic cells through recognition of acommon ligand: phosphorylcholine of oxidized phospholipids, PNAS 99
(2002) 13043–13048.
[69] V.N. Bochkov, A. Kadl, J. Huber, F. Gruber, B.R. Binder, N. Leitinger,
Protective role for phospholipid oxidation products in endotoxin-induced
tissue damage, Nature 419 (2002) 77–81.
[70] A. Rigotti, S.L. Acton, M. Krieger, The class B scavenger receptors SR-
BI and CD36 are receptors for anionic phospholipids, J. Biol. Chem. 270
(1995) 16221–16224.
[71] O.S. Rahaman, D.J. Lennon, M. Febbraio, E.A. Podrez, S.L. Hazen, R.L.
Silverstein, A CD36-dependent signaling cascade is necessary for
macrophage foam cell formation, Cell Metab. 4 (2006) 211–221.
[72] M. Febbraio, E.A. Podrez, J.D. Smith, D.P. Hajjar, S.L. Hazen, H.F. Hoff,
K. Sharma, R.L. Silverstein, Targeted disruption of the class B scavenger
receptor CD36 protects against atherosclerotic lesion development in
mice, J. Clin. Invest. 105 (2000) 1049–1056.
[73] A.C. Nicholson, S. Frieda, A. Pearce, R.L. Silverstein, Oxidized LDL
binds to CD36 on human monocyte-derived macrophages and transfected
cell lines: evidence implicating the lipid moiety of the lipoprotein as the
binding site, Arterioscler. Thromb. Vasc. Biol. 15 (1995) 269–275.
[74] E.A. Podrez, M. Febbraio, N. Sheibani, D. Schmitt, R.L. Silverstein, D.P.
Hajjar, P.A. Cohen, W.A. Frazier, H.F. Hoff, S.L. Hazen, Macrophage
scavenger receptor CD36 is the major receptor for LDL modified by
monocyte-generated reactive nitrogen species, J. Clin. Invest. 105 (2000)
1095–1108.
[75] R.L. Silverstein, A.S. Asch, R.L. Nachman, Glycoprotein IV Mediates
Thrombospondin-Dependent Platelet-Monocyte and Platelet-U937 Cell
Adhesion, 1989, pp. 546–552.
[76] R.L. Silverstein,M. Febbraio, CD36 and Atherosclerosis, 2000, pp. 483–491.
[77] J.F. Tait, C. Smith, Phosphatidylserine receptors: role of CD36 in binding
of anionic phospholipid vesicles to monocytic cells, J. Biol. Chem. 274
(1999) 3048–3054.
[78] N. Abumrad, C. Coburn, A. Ibrahimi, Membrane proteins implicated in
long-chain fatty acid uptake by mammalian cells: CD36, FATP and
FABPm, Biochim. Biophys. Acta 1441 (1999) 4–13.
[79] M.D.P. Navazo, L. Daviet, E. Ninio, J.L. McGregor, Identification on
human CD36 of a domain (155–183) implicated in binding oxidized low-
density lipoproteins (Ox-LDL), Arterioscler. Thromb. Vasc. Biol. 16
(1996) 1033–1039.
[80] S.F. Pearce, P. Roy, A.C. Nicholson, D.P. Hajjar, M. Febbraio, R.L.
Silverstein, Recombinant glutathione S-transferase/CD36 fusion proteins
define an oxidized low density lipoprotein-binding domain, J. Biol.
Chem. 273 (1998) 34875–34881.
[81] A. Yamaguchi, N. Yamamoto, N. Akamatsu, T.C. Saido, M. Umeda, K.
Tanoue, PS-liposome and ox-LDL bind to different sites of the
immunodominant domain (#155–183) of CD36: a study with GS95, a
new anti-CD36 monoclonal antibody, Thromb. Res. 97 (2000) 317–326.
[82] E.A. Podrez, G. Hoppe, J. Neil, H.F. Hoff, Phospholipids in oxidized
LDL not adducted to apoB are recognized by the CD36 scavenger
receptor, Free Radic. Biol. Med. 34 (2003) 356–364.
[83] E.A. Podrez, E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P.J. Finton,
L. Shan, M. Febbraio, D.P. Hajjar, R.L. Silverstein, H.F. Hoff, R.G.
Salomon, S.L. Hazen, A novel family of atherogenic oxidized phospho-
lipids promotes macrophage foam cell formation via the scavenger receptor
CD36 and is enriched in atherosclerotic lesions, J. Biol. Chem. 277 (2002)
38517–38523.
[84] M.F. Tsan, B. Gao, Endogenous ligands of Toll-like receptors, J. Leukoc.
Biol. 76 (2004) 514–519.
[85] X.H. Xu, P.K. Shah, E. Faure, Toll-like receptor 4 is expressed by
macrophages in murine and human lipid-rich atherosclerotic plaques and
upregulated by oxidized LDL, Circulation 104 (2001) 3103–3108.
[86] K.A. Walton, A.L. Cole, M. Yeh, G. Subbanagounder, S.R. Krutzik, R.L.
Modlin, R.M. Lucas, J. Nakai, E.J. Smart, D.K. Vora, J.A. Berliner, Specific
phospholipid oxidation products inhibit ligand activation of toll-like
receptors 4 and 2, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1197–1203.
[87] S. Pegorier, D. Stengel, H. Durand, M. Croset, E. Ninio, Oxidized
phospholipid: POVPC binds to platelet-activating-factor receptor on
human macrophages: implications in atherosclerosis, Atherosclerosis 188
(2006) 433–443.
735G.O. Fruhwirth et al. / Biochimica et Biophysica Acta 1772 (2007) 718–736[88] F. Parhami, Z.T. Fang, B. Yang, A.M. Fogelman, J.A. Berliner,
Stimulation of Gs and inhibition of Gi protein functions by minimally
oxidized LDL, Arterioscler. Thromb. Vasc. Biol. 15 (1995) 2019–2024.
[89] H. Obinata, T. Hattori, S. Nakane, K. Tatei, T. Izumi, Identification of 9-
hydroxyoctadecadienoic acid and other oxidized free fatty acids as
ligands of the G Protein-coupled receptor G2A, J. Biol. Chem. 280 (2005)
40676–40683.
[90] Z. Weng, A.C. Fluckiger, S. Nisitani, M.I. Wahl, L.Q. Le, C.A. Hunter, A.A.
Fernal, M.M. Le Beau, O.N. Witte, A DNA damage and stress inducible G
protein-coupled receptor blocks cells in G2/M, PNAS 95 (1998)
12334–12339.
[91] R. Li, K.P. Mouillesseaux, D. Montoya, D. Cruz, N. Gharavi, M. Dun, L.
Koroniak, J.A. Berliner, Identification of prostaglandin E2 receptor subtype
2 as a receptor activated by OxPAPC, Circ. Res. 98 (2006) 642–650.
[92] G.K. Hansson, Cell-mediated immunity in atherosclerosis, Curr. Opin.
Lipidol. 8 (1997) 311.
[93] P. Libby, G.K. Hansson, J.S. Pober, Atherogenesis and Inflammation, in:
K.R. Chien (Ed.), Molecular Basis of Cardiovascular Disease, W.B.
Saunders, Philadelphia, 1999, pp. 349–366.
[94] J.L. Witztum, W. Palinski, Are immunological mechanisms relevant for
the development of atherosclerosis? Clin. Immunol. 90 (1999) 156.
[95] P. Libby, D. Egan, S. Skarlatos, Roles of infectious agents in
atherosclerosis and restenosis: an assessment of the evidence and need
for future research, Circulation 96 (1997) 4103.
[96] W. Palinski, T. Koschinsky, S.W. Butler, E. iller, H. Vlassara, A. Cerami,
J.L. Witztum, Immunological evidence for the presence of advanced
glycosylation end products in atheroslcerotic lesions of euglycemic
rabbits, Arterioscler. Thromb. Vasc. Biol. 15 (1995) 582.
[97] G. Wick, H. Perschinka, Q. Xu, Autoimmunity and atherosclerosis, Am.
Heart J. 138 (1999) S449.
[98] S. Hörkkö, D.A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbana-
gounder, J.A. Berliner, P. Friedman, E.A. Dennis, L.k. Curtiss, W.
Palinski, J.L. Witztum, Monoclonal autoantibodies specific for oxidized
phospholipids or oxidized phospholipid–protein adducts inhibit macro-
phage uptake of oxidized low density lipoproteins, J. Clin. Invest. 103
(1998) 117–128.
[99] S. Hörkkö, E. Miller, E. Dudl, P. Reaven, L.K. Curtiss, N.J. Zvaifler, R.
Terkeltaub, S.S. Pierangeli, D.W. Branch, W. Palinski, J.L. Witztum,
Antiphospholipid antibodies are directed against epitopes of oxidized
phospholipids. Recognition of cardiolipin by monoclonal antibodies to
epitopes of oxidized low density lipoprotein, J. Clin. Invest. 98 (1996) 825.
[100] S. Hörkko, E.Miller, D.W. Branch, W. Palinski, J.L.Witztum, The epitopes
for some antiphospholipid antibodies are adducts of oxidized phospholipid
and beta2 glycoprotein 1 (and other proteins), Proc. Natl. Acad. Sci. U. S.A.
94 (1997) 10361.
[101] M.K. Chang, C. Bergmark, A. Laurila, S. Horkko, K.H. Han, P.
Friedman, E.A. Dennis, J.L. Witztum, Monoclonal antibodies against
oxidized low-density lipoprotein bind to apoptotic cells and inhibit their
phagocytosis by elicited macrophages: Evidence that oxidation-specific
epitopes mediate macrophage recognition, PNAS 96 (1999) 6353–6358.
[102] J.A. Berliner, G. Subbanagounder, N. Leitinger, A.D. Watson, D. Vora,
Evidence for a role of phospholipid oxidation products in atherogenesis,
Trends Cardiovasc. Med. 11 (2001) 142–147.
[103] N. Leitinger, T.R. Tyner, L. Oslund, C. Rizza, G. Subbanagounder, H. Lee,
P.T. Shih, N. Mackman, G. Tigyi, M.C. Territo, J.A. Berliner, D.K. Vora,
Structurally similar oxidized phospholipids differentially regulate endothe-
lial binding of monocytes and neutrophils, PNAS 96 (1999) 12010–12015.
[104] P.T. Shih, M.J. Elices, Z.T. Fang, T.P. Ugarova, D. Strahl, M.C. Territo, J.S.
Frank, N.L. Kovach, C. Cabanas, J.A. Berliner, Minimally modified low-
density lipoprotein induces monocyte adhesion to endothelial connecting
segment-1 by activating beta 1 integrin, J. Clin. Invest. 103 (1999) 613–625.
[105] A.L. Cole, G. Subbanagounder, S. Mukhopadhyay, J.A. Berliner, D.K.
Vora, Oxidized phospholipid-induced endothelial cell/monocyte interac-
tion is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway,
Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1384–1390.
[106] M. Navab, S.Y. Hama, S.T. Ready, C.J. Ng, B.J. Van Lenten, H. Laks, A.M.
Fogelman, Oxidized lipids as mediators of coronary heart disease, Curr.
Opin. Lipidol. 13 (2002) 363–372.[107] V.N. Bochkov, D. Mechtcheriakova, M. Lucerna, J. Huber, R. Malli, W.F.
Graier, E. Hofer, B.R. Binder, N. Leitinger, Oxidized phospholipids
stimulate tissue factor expression in human endothelial cells via
activation of ERK/EGR-1 and Ca+/NFAT, Blood 99 (2002) 199–206.
[108] A. Zimman, K.P. Mouillesseaux, T. Le, N.M. Gharavi, A. Ryvkin, T.G.
Graeber, T.T. Chen, A.D. Watson, J.A. Berliner, Vascular endothelial growth
factor receptor 2 plays a role in the activation of aortic endothelial cells by
oxidized phospholipids,Arterioscler. Thromb.Vasc.Biol. 27 (2007) 332–338.
[109] S.T. Reddy, S. Hama, V. Grijalva, K. Hassan, R. Mottahedeh, G. Hough,
D.J. Wadleigh, M. Navab, A.M. Fogelman, Mitogen-activated protein
kinase phosphatase 1 activity is necessary for oxidized phospholipids to
induce monocyte chemotactic activity in human aortic endothelial cells,
J. Biol. Chem. 276 (2001) 17030–17035.
[110] S.T. Reddy, V. Grijalva, C. Ng, K. Hassan, S. Hama, R. Mottahedeh, D.J.
Wadleigh, M. Navab, A.M. Fogelman, Identification of genes induced by
oxidized phospholipids in human aortic endothelial cells, Vasc. Pharmacol.
38 (2002) 211–218.
[111] J. Huber, A. Furnkranz, V.N. Bochkov,M.K. Patricia, H. Lee, C.C.Hedrick,
J.A. Berliner, B.R. Binder, N. Leitinger, Specific monocyte adhesion to
endothelial cells induced b oxidized phospholipids involves activation of
cPLA2 and lipoxygenase, J. Lipid Res. 47 (2006) 1054–1062.
[112] M.K. Patricia, R. Natarajan, A.N. Dooley, F. Hernandez, J.L. Gu, J.A.
Berliner, J.J. Rossi, J.L. Nadler, R.S. Meidell, C.C. Hedrick, Adenoviral
delivery of a leukocyte-type 12 lipoxygenase ribozyme inhibits effects of
glucose and plateletderived growth factor in vascular endothelial and
smooth muscle cells, Circ. Res. 88 (2001) 659–665.
[113] H. Lee, W. Shi, P. Tontonoz, S. Wang, G. Subbanagounder, C.C. Hedrick,
S. Hama, C. Borromeo, R.M. Evans, J.A. Berliner, L. Nagy, Role for
peroxisome proliferator-activated receptor {alpha} in oxidized phospho-
lipid-induced synthesis of monocyte chemotactic protein-1 and interleu-
kin-8 by endothelial cells, Circ. Res. 87 (2000) 516–521.
[114] G. Subbanagounder, J.W. Wong, H. Lee, K.F. Faull, E. Miller, J.L.
Witztum, J.A. Berliner, Epoxyisoprostane and epoxycyclopentenone
phospholipids regulate monocyte chemotactic protein-1 and interleukin-
8 synthesis, J. Biol. Chem. 277 (2002) 7271–7281.
[115] M. Yeh, N.M. Gharavi, J. Choi, X. Hsieh, E. Reed, K.P. Mouillesseaux,
A.L. Cole, S.T. Reddy, J.A. Berliner, Oxidized phospholipids increase
interleukin 8 (IL-8) synthesis by activation of the c-src/signal transducers
and activators of transcription (STAT)3 pathway, J. Biol. Chem. 279
(2004) 30175–30181.
[116] M. Yeh, N. Leitinger, R. de Martin, N. Onai, K. Matsushima, D.K. Vora,
J.A. Berliner, S.T. Reddy, Increased transcription of IL-8 in endothelial
cells is differentially regulated by TNF-{alpha} and oxidized phospho-
lipids, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1585–1591.
[117] N.M. Gharavi, P.S. Gargalovic, I. Chang, J.A. Araujo, M.J. Clark, W.
Lam Szeto, A.D. Watson, A.J. Lusis, J.A. Berliner, High-Density
Lipoprotein Modulates Oxidized Phospholipid Signaling in Human
Endothelial Cells From Proinflammatory to Anti-inflammatory, Circ.
Res. 98 (6) (2006) 768–776.
[118] N.M. Gharavi, N.A. Baker, K.P. Mouillesseaux, W. Yeung, H.M. Honda,
X. Hsieh, M. Yeh, E.J. Smart, J.A. Berliner, Role of endothelial nitric
oxide synthase in the regulation of SREBP activation by oxidized
phospholipids, Circ. Res. 98 (2006) 768–776.
[119] E. Niki, Y. Yoshida, Y. Saito, N. Noguchi, Lipid peroxidation:
mechanisms, inhibition, and biological effects, Biochem. Biophys. Res.
Commun. 338 (2005) 668–676.
[120] G. Subbanagounder, Y. Deng, C. Borromeo, A.N. Dooley, J.A. Berliner,
R.G. Salomon, Hydroxy alkenal phospholipids regulate inflammatory
functions of endothelial cells, Vasc. Pharmacol. 38 (2002) 201–209.
[121] Z. Ma, J. Li, L. Yang, Y. Mu, W. Xie, B. Pitt, S. Li, Inhibition of LPS- and
CpG DNA-induced TNFa response by oxidized phospholipids, Am.
J. Physiol., Lung Cell Mol. Physiol. 286 (2004) L808–L816.
[122] K.A. Walton, B. Gugiu, M. Thomas, R.J. Basseri, D.R. Eliav, R.G.
Salomon, J.A. Berliner, A role for neutral sphingomyelinase activation in
the inhibition of LPS action by phospholipid oxidation products, J. Lipid
Res. 47 (2006) 1967–1974.
[123] A. Kadl, J. Huber, F. Gruber, V.N. Bochkov, B.R. Binder, N. Leitinger,
Analysis of inflammatory gene induction by oxidized phospholipids in
736 G.O. Fruhwirth et al. / Biochimica et Biophysica Acta 1772 (2007) 718–736vivo by quantitative real-time RT-PCR in comparison with effects of LPS,
Vasc. Pharmacol. 38 (2002) 219–227.
[124] S.M. Prescott, T.M. McIntyre, G.A. Zimmerman, D.M. Stafforini,
Molecular events in acute inflammation, Arterioscler. Thromb. Vasc.
Biol. 22 (2002) 727–733.
[125] J.M. Heery, M. Kozak, D.M. Stafforini, D.A. Jones, G. Zimmerman, T.M.
McIntyre, Oxidatively modified LDL contains phospholipids with PAF-
like activity and stimulates the growth of smooth muscle cells, J. Clin.
Invest. 96 (1995) 2322–2330.
[126] G.K. Marathe, G.A. Zimmerman, S.M. Prescott, T.M. McIntyre,
Activation of vascular cells by PAF-like lipids in oxidized LDL, Vasc.
Pharmacol. 38 (2002) 193–200.
[127] A.V. Ponstler, A.S. Hilaire, G.K. Marathe, G. Zimmerman, T.M. McIntyre,
Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator
activated receptor Æ and oxidized alkyl phospholipids from oxidized low
density lipoprotein, J. Biol. Chem. 277 (2002) 13029–16036.
[128] P.S. Gargalovic, M. Imura, B. Zhang, N.M. Gharavi, M.J. Clark, J.
Pagnon, W.P. Yang, A. He, A. Truong, S. Patel, S.F. Nelson, S. Horvath,
J.A. Berliner, T.G. Kirchgessner, A.J. Lusis, Identification of inflamma-
tory gene modules based on variations of human endothelial cell
responses to oxidized lipids, PNAS 103 (2006) 12741–12746.
[129] W. Martinet, M.M. Kockx, Apoptosis in atherosclerosis: focus on oxidized
lipids and inflammation, Curr. Opin. Lipidol. 12 (2001) 535–541.
[130] M.J. Pollman, J.L. Hall, M.J. Mann, L. Zhang, G.H. Gibbons, Inhibition
of neointimal cell Bcl-x expression induces apoptosis and regression of
vascular disease, Nat. Med. 4 (1998) 222–227.
[131] B.Y. Wang, H.K. Ho, P.S. Lin, S.P. Schwarzacher, M.J. Pollman, G.H.
Gibbons, P.S. Tsao, J.P. Cooke, Regression of atherosclerosis: role of
nitric oxide and apoptosis, Circulation 99 (1999) 1236–1241.
[132] M.M. Kockx, Apoptosis in atherosclerotic plaques. Quantitative and
qualitative aspects, Arterioscler. Thromb.Vasc. Biol. 18 (1998) 1519–1522.
[133] P. Libby, Y.J. Geng, G.K. Sukhova, D.I. Simon, R.T. Lee, Molecular
determinants of atherosclerotic plaque vulnerability, Ann. N.Y. Acad. Sci.
811 (1997) 134–142.
[134] J. Huber, A. Vales, G. Mitulovic, M. Blumer, R. Schmid, J.L. Witztum, B.R.
Binder, N. Leitinger, Oxidized membrane vesicles and blebs from apoptotic
cells contain biologically active oxidized phospholipids that induce
monocyte–endothelial interactions, Arterioscler. Thromb. Vasc. Biol. 22
(2002) 101–107.
[135] A. Arroyo, M.Modriansky, F.B. Serinkan, R.I. Bello, T. Matsura, J. Jiang,
V.A. Tyurin, Y.Y. Tyurina, B. Fadeel, V.E. Kagan, NADPH oxidase-
dependent oxidation and externalization of phosphatidylserine during
apoptosis in Me2SO-differentiated HL-60 cells. Role in phagocytic
clearance, J. Biol. Chem. 277 (2002) 19965–49975.
[136] V.E. Kagan, J.P. Fabisiak, A.A. Shvedova, Y.Y. Tyurina, V.A. Tyurin, N.F.
Schor, K. Kawai, Oxidative signaling pathway for externalization of plasma
membrane phosphatidylserine during apoptosis, FEBSLett. 477 (2000) 1–7.
[137] K.D. Patel, G. Zimmerman, S.M. Prescott, T.M. McIntyre, Novel
leukocyte agonists are released by endothelial cells exposed to peroxide,
J. Biol. Chem. 267 (1992) 15168–15175.
[138] M.K. Chang, B. Binder, D.B. Miller, G. Subbanagounder, G. Silverman, J.A.
Berliner, J.L. Witztum, Apoptotic cells with oxidation-specific epitopes are
immunogenic and proinflammatory, J. Exp. Med. 200 (2004) 1359–1370.
[139] A. Loidl, E. Sevcsik, G. Riesenhuber, H.P. Deigner, A. Hermetter,
Oxidized phospholipids in minimally modified low density lipoprotein
induce apoptotic signaling via activation of acid sphingomyelinase in
arterial smooth muscle cells, J. Biol. Chem. 278 (2003) 32921–32928.
[140] A. Tokumura, T. Sumida, M. Toujima, K. Kogure, K. Fukuzawa, Platelet-
derived factor (PAF)-like oxidized phospholipids: relevance to athero-
sclerosis, BioFactors 13 (2000) 29–33.
[141] K. Kogure, S. Nakashima, A. Tsuchie, A. Tokumura, K. Fukuzawa,
Temporary membrane distortion of vascular smooth muscle cells is
responsible for their apoptosis induced by platelet-activating factor-like
oxidized phospholipids and their degradation product, lysophosphatidyl-
choline, Chem. Phys. Lipids 126 (2003) 29–38.
[142] S. Kalyankrishna, J.H. Parmentier, K.U. Malik, Arachidonic acid-derived
oxidation products initiate apoptosis in vascular smooth muscle cells,
Prostaglandins Other Lipid Mediat. 70 (2002) 13–29.[143] A. Moumtzi, M. Trenker, K. Flicker, E. Zenzmaier, R. Saf, A. Hermetter,
Import and fate of fluorescent analogs of oxidized phospholipids in
vascular smooth muscle cells, J. Lipid Res. 48 (2006) 565–582.
[144] E. Waddington, K. Sienuarine, I. Puddey, K. Croft, Identification and
quantitation of unique fatty acid oxidation products in human atheroscle-
rotic plaque using high-performance liquid chromatography, Anal.
Biochem. 292 (2001) 234–244.
[145] A.D.Watson, N. Leitinger,M.Navab,K.F. Faull, S. Horkko, J.L.Witztum,W.
Palinski, D. Schwenke, R.G. Salomon, W. Sha, G. Subbanagounder, A.M.
Fogelman, J.A. Berliner, Structural identification by mass spectrometry of
oxidized phospholipids in minimally oxidized low density lipoprotein that
induce monocyte/endothelial interactions and evidence for their presence in
vivo, J. Biol. Chem. 272 (1997) 13597–13607.
[146] D. Pratico, L. Iuliano, A.Mauriello, L. Spagnoli, J.A. Lawson, J. Rokach, J.
Maclouf, F. Violi, G.A. Fitzgerald, Localization of distinct F2-isoprostanes
in human atherosclerotic lesions, J. Clin. Invest. 100 (1997) 2028–2034.
[147] C. Gniwotta, J.D. Morrow, L.J. Roberts II, H. Kuhn, Prostaglandin F2-like
compounds, F2-isoprostanes, are present in increased amounts in human ath-
erosclerotic lesions, Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3236–3241.
[148] R.G. Salomon, E. Batyreva, K. Kaur, D.L. Sprecher, M.J. Schreiber, J.W.
Crabb, M.S. Penn, A.M. DiCorleto, S.L. Hazen, E.A. Podrez, Isolevu-
glandin–protein adducts in humans: products of free radical-induced lipid
oxidation through the isoprostane pathway, Biochim. Biophys. Acta 1485
(2000) 225–235.
[149] V.N. Bochkov, M. Philippova, O. Oskolkova, A. Kadl, A. Furnkranz, E.
Karabeg, T. Afonyushkin, F. Gruber, J. Breuss, A. Minchenko, D.
Mechtcheriakova, P. Hohensinner, K. Rychli, J. Wojta, T. Resink, P. Erne,
B.R. Binder, N. Leitinger, Oxidized phospholipids stimulate angiogenesis
via autocrine mechanisms, implicating a novel role for lipid oxidation in
the evolution of atherosclerotic lesions, Circ. Res. 99 (2006) 900–908.
[150] S. Chatterjee, J.A. Berliner, G. Subbanagounder, A.K. Bhunia, S. Koh,
Identification of a biologically active component in minimally oxidized
low density lipoprotein (MM-LDL) responsible for aortic smooth muscle
cell proliferation, Glycoconj. J. 20 (2004) 331–338.
[151] K.G. Birukov, V.N. Bochkov, A.A. Birukova, K. Kawkitinarong, A. Rios,
A. Leitner, A.D. Verin, G.M. Bokoch, N. Leitinger, J. Garcia,
Epoxycyclopentenone-containing oxidized phospholipids restore endo-
thelial barrier function via Cdc42 and Rac, Circ. Res. 95 (2004) 892–901.
[152] S. Eligini, M. Brambilla, C. Banfi, M. Camera, L. Sironi, S.S. Barbieri, J.
Auwerx, E. Tremoli, S. Colli, Oxidized phospholipids inhibit cycloox-
ygenase-2 in human macrophages via nuclear factor-kB/IkB and ERK2
dependent mechanisms, Cardiovasc. Res. 55 (2002) 406–415.
[153] M. Yeh, A.L. Cole, J. Choi, Y. Liu, D. Tulchinsky, J.H. Qiao, M.C.
Fishbein, A.N. Dooley, T. Hovnanian, K. Mouilleseaux, D.K. Vora, W.P.
Yang, P. Gargalovic, T. Kirchgessner, J.Y. Shyy, J.A. Berliner, Role for
sterol regulatory element-binding protein in activation of endothelial cells
by phospholipid oxidation products, Circ. Res. 95 (2004) 780–788.
[154] K.G. Birukov, N. Leitinger, V.N. Bochkov, J.G.N. Garcia, Signal
transduction pathways activated in human pulmonary endothelial cells
by OxPAPC, a bioactive component of oxidized lipoproteins, Microvasc.
Res. 67 (2004) 18–28.
[155] G. Krönke, V.N. Bochkov, J. Huber, F. Gruber, S. Blüml, A. Fürnkranz, A.
Kadl, B.R. Binder, N. Leitinger, Oxidized phospholipids induce expression
of human heme oxygenase-1 involving activation of cAMP-responsive
element-binding protein, J. Biol. Chem. 278 (2003) 51006–51014.
[156] H. Ishii, T. Tezuka, H. Ishikawa, K. Takada, K. Oida, S. Horie, Oxidized
phospholipids in oxidized low-density lipoprotein down-regulate thrombo-
modulin transcription in vascular endothelial cells through a decrease in the
binding of RAR{beta}-RXR{alpha} heterodimers and Sp1 and Sp3 to their
binding sequences in the TM promoter, Blood 101 (2003) 4765–4774.
[157] J. Hartwich, A. Dembinska-Kiec, A. Gruca, M. Motyka, L. Partyka, J.
Skrzeczynska, M. Bzowska, J. Pryjma, J. Huber, N. Leitinger, G.
Schmitz, Regulation of platelet adhesion by oxidized lipoproteins and
oxidized phospholipids, Platelets 13 (2002) 141–151.
[158] A. Furnkranz, A. Schober, V.N. Bochkov, P. Bashtrykov, G. Kronke, A.
Kadl, B.R. Binder, C.Weber, N. Leitinger, Oxidized phospholipids trigger
atherogenic inflammation in murine arteries, Arterioscler. Thromb. Vasc.
Biol. 25 (2005) 633–638.
